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ABSTRACT OF DISSERTATION 
 
 
 
NM23-H1 BLOCKS CELL MOTILITY INDEPENDENTLY OF ITS KNOWN 
ENZYMATIC ACTIVITIES IN A COHORT OF HUMAN MELANOMA CELLS 
 
 
The metastasis suppressor gene NM23-H1 has been shown to possess 
three enzymatic activities including nucleoside diphosphate kinase, histidine-
dependent protein kinase and 3’-5’ exonuclease activity.  While these properties 
have been demonstrated in vitro using recombinant proteins, the contribution of 
these activities to suppression of metastatic dissemination is unknown.  Site-
directed mutagenesis studies were used to identify amino acid residues which 
are required for proper function of each enzymatic activity associated with H1, 
providing a platform for studying the importance of each function on an individual 
basis.  To assess the relevance of these activities to melanoma progression, a 
panel of mutants harboring selective lesions disrupting the enzymatic activities of 
H1 were overexpressed using stable transfection in two melanoma cell lines, 
WM793 (isolated from a vertical growth phase human melanoma), and the 
metastatic derivative cell line 1205LU.  In vitro correlates of metastasis 
measuring motility and invasion were used in an attempt to identify the 
mechanism mediating H1-dependent motility suppression of cancer cells.  
Surprisingly, all mutants studied retained full motility suppression in this setting, 
suggesting that the enzymatic functions associated with H1 are not required for 
inhibiting cell migration.  Instead, gene expression analyses conducted on the 
panel of stable transfectants indicate that differences in steady-state mRNA 
levels of genes involved in mitogen-activated protein kinase (MAPK) signaling 
showed significant correlations with H1 expression and motility suppression.  
RNAi studies have confirmed that H1-dependent modulation of the expression of 
two genes in particular, BRAP and IQGAP2, contribute to the observed 
phenotype, suggesting a novel mechanism used by NM23 to control cellular 
migration in human melanoma.       
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CHAPTER ONE 
Background 
 
Metastasis and Suppressor Genes 
The process of tumorigenic transformation and subsequent malignant 
progression of human cells is driven by genetic and epigenetic alterations that 
disrupt both intracellular and extracellular homeostasis.  This leads to disruption 
of normal cellular physiology and produces cells which no longer respond 
appropriately to contextual cues causing uncontrolled proliferation, culminating in 
the formation of a primary tumor.  As the tumor grows and the population of cells 
rapidly expands, it is thought that a small subset of these cells acquire additional 
changes which provide a selective advantage by displaying increased plasticity.  
These cells are then equipped with an enhanced adaptive response that allows 
them to respond (or fail to respond) to various stimuli outside of the normal 
repertoire of signaling cues found in the tissue-of-origin, permitting them to thrive 
in otherwise foreign microenvironments.  Although it is still unclear what exactly 
initiates the conversion of a benign growth to a malignancy, cancer cells that are 
able to disseminate from the primary tumor, travel and survive in the circulation 
or lymphatics, then colonize and proliferate at a new site are deemed metastatic.  
Metastasis is a complex, multi-stepped process (Figure 1.1) paramount to the 
pathology of cancer as it is responsible for greater than 90% of the deaths of 
those that succumb to malignant tumors (1).  In spite of this, an unbelievably 
small amount of cancer research funding is dedicated to metastasis research (2).  
This seems counterintuitive based on the morbidity associated with metastatic 
disease and the accumulating evidence suggesting tumorigenesis and 
metastasis are distinct processes controlled by unique mechanisms (3, 4).  It is 
known that disrupting a single step in the metastatic cascade can prevent the 
formation of secondary tumors (5), enhancing the number of possibilities for 
unique therapeutic intervention.  With greater understanding, the clinical impact 
from this would appear to be extremely promising as disrupting a process known 
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Figure 1.1 Schematic of the Necessary Steps in Metastasis (from (6)).  This 
illustration of the highly dynamic process of metastasis reinforces the idea that a 
cell must be extremely plastic in order to successfully adapt to the many stresses 
and rapidly changing microenvironments it will encounter during the transition. 
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to specifically drive metastatic dissemination almost certainly would have a much 
greater impact on patient survival than current treatments. 
Distinguishing features of metastasis versus tumorigenesis have become 
more abundant over the past 20 years as more than twenty members of a class 
of genes known as metastasis suppressors have been identified to date (7).  A 
metastasis suppressor gene (MSG) is defined as an inhibitor of metastatic 
dissemination that has little or no apparent impact on growth of the primary 
tumor.  Examples of MSG’s include KISS1 (8), RhoGDI2 (9), Caspase-8 (10), 
MKK-4,-6 &-7 (11-13), RKIP (14) and BRMS1 (15).  Most data investigating the 
function of these genes in metastatic contexts suggest that their products have 
roles in highly conserved eukaryotic signaling cascades and may actually restore 
signaling programs that mimic that of their normal or benign cellular counterparts 
(15).  The biological processes associated with the MSG’s have led them to be 
separated into 4 classes based on the type of intracellular network that they are 
associated with: cytoskeletal, mitogenic, stress-activated or survival signaling.  
These activities commonly impact a cell’s motility, morphology, growth and 
evasion of apoptosis, all traits highly correlated with cancer and metastasis.  The 
wide variety of physiological functions attributed to this class of genes again 
underscores the disease’s complexity, yet highlights a uniquely attractive means 
of treating metastasis.  MSGs have been identified based on consistent patterns 
of reduced expression in highly metastatic cancers, suggesting negative 
selective pressure for these genes in the most aggressive cells.  Therefore, the 
exploitation of these genes for use as therapeutics has generated a great deal of 
interest, as it is thought stimulation of MSG expression by chemical means or via 
gene therapy may hold promise for preventing advanced disease.  
 
NM23 Gene Family 
The first described metastasis suppressor gene was NM23-H1 (H1) which 
was initially identified in models of murine melanoma and human breast cancer 
as having significantly reduced expression in highly metastatic clones as 
compared to the congenic non-metastatic counterparts (16).  Since then, 
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overexpression of H1 has been shown to reduce the metastatic potential of 
cancer cells derived from melanoma (17-19), breast (20, 21), colon (22), ovarian 
(23) and oral squamous cell carcinomas (24).  In agreement with these studies, 
nm23- knockout mice exhibited more pulmonary metastases in a model of 
hepatocellular carcinoma while showing no significant impact on the formation of 
the primary tumor (25).  Although it has been more than two decades since the 
original designation of NM23-H1 as a metastasis suppressor, the mechanism of 
inhibition has remained elusive in spite of a wealth of experimental data 
characterizing the molecule in a wide variety of contexts.   
The NM23 family of proteins is encoded by 10 genes in humans which are 
commonly designated –H1 to –H9 (gene symbol: NME1-9), along with the 
recently added RP2 gene (NME10). The unifying feature of this family is their 
evolutionarily conserved nucleoside diphosphate kinase (ndpk) protein domain, 
an archain peptide sequence also found in many prokaryotes. Surprisingly, only 
isoforms H1-H4, which function as hexamers, & H6 actually exhibit ndpk activity 
(26).  The NM23 gene family is involved in a number of cellular processes such 
as differentiation, development, apoptosis and metastasis suppression.  The H1 
isoform along with the highly homologous H2 have been studied most 
extensively in a variety of contexts and have been shown to consistently block 
metastasis.  Experimental characterization of H1in particular has elucidated in 
vitro biochemical activities in addition to ndpk, including a 3’-5’ exonuclease 
activity and a histidine-dependent protein kinase function.  The contribution of 
each activity to H1-mediated metastasis suppression at this point is unclear. 
 
Nucleoside Diphosphate Kinase 
The ndpk function generates nucleoside triphosphates (NTP) from 
nucleoside diphosphates at the expense of other NTPs, usually adenosine-
triphosphates (ATP).  This process is catalyzed by the ndpk-dependent transfer 
of a high-energy -phosphate from one nucleotide to the other.  This terminal 
phosphate binds to an ndpk such as NM23, forming a phosphor-enzyme 
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intermediate through a “ping-pong” type of transfer mechanism (27).  A simplified 
schematic is presented below: 
 
         ndpk 
N1DP + N2TP                       N1TP + N2DP 
 
 
Biologically, this was initially thought to be a nonessential “housekeeping” 
function present to promote balance among nucleotide pools in various cellular 
compartments.  However, it has become evident that H1 has diverse influences 
on cellular development and homeostasis, some of which may indeed rely more 
on ndpk than originally appreciated.  For example, several studies have been 
conducted to specifically examine the contribution of the ndpk activity to the 
metastasis suppressor function of H1 (28-31).  Although these reports showed 
ndpk activity to be unnecessary for suppression, full investigation into the 
contribution of this activity with in vivo models of spontaneous metastatic tumor 
growth were not completed until recently and the resulting data would suggest 
otherwise (32).  Furthermore, evidence from various experimental systems has 
shown the importance for this function in regulating metabolic processes in both 
the cytosol and in mitochondria, as well as for the generation of NTPs necessary 
for synthesis of nucleic acids (33).  The contribution of the lattermost function on 
the efficiency of DNA replication and repair is illustrated by an acquired mutator 
phenotype observed in E. coli lacking ndk, the bacterial homolog of NM23 (34).  
It is thought that this gene family may have similar roles in eukaryotic systems as 
well (35).   
 
Histidine-dependent Protein Kinase 
 The description of the histidine-dependent protein kinase activity of H1 
first appeared in the literature in 1995 when H1-dependent phosphorylation of a 
histidine residue in the ATP-citrate lyase gene product was reported (36).  A 
number of other substrates have since been identified including porcine succinyl 
thiokinase (37), kinase suppressor of ras (KSR) (38) and aldolase C (39).  The 
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mechanism of action is similar to ndpk with the formation of a high-energy 
phosphorylated intermediate but transfer of the terminal phosphate is directed 
toward protein substrates instead of nucleoside diphosphates.  So far, the best 
case for an inherent function mediating the metastasis suppressor function of 
NM23 has been made for the histidine kinase activity as it has been reported to 
mediate motility suppression and anchorage-dependent growth in a number of 
cancer cell types (40-42).  This effect appears to be the result of H1-dependent 
phosphorylation of KSR, a scaffolding molecule important for propagation of MAP 
kinase signals through Raf and MEK.  From the large collection of data 
implicating the MAPK cascade in tumor progression, quite a bit of interest is now 
focused on H1-mediated suppression of Raf signaling via KSR, and its role in 
metastasis. 
 
3’-5’ Exonuclease 
 Our lab was the first to describe the third endogenous activity of NM23-
H1, a 3’-5’ exonuclease function which was shown to preferentially remove 
overhanging or mismatched bases at the 3’ end of deoxyribonucleotide oligomers 
(43).  This finding has generated considerable excitement as 3’-5’ exonucleases 
commonly have roles in DNA repair processes, the disruption of which has been 
repeatedly linked to tumorigenesis (44, 45).  In addition, this activity could play 
significant roles in metastatic disease by helping preserve genomic integrity.  
Highly metastatic cells have elevated spontaneous genomic mutation rates when 
compared to less metastatic counterparts (46), supporting the notion that the 
exonuclease activity of H1 could be a contributing factor to suppressor function.   
The ability of the H1 isoform to cleave DNA was not a complete surprise. It had 
previously been shown that the highly homologous NM23-H2 possessed 
nuclease activity, targeting nuclease hyper-sensitive elements of the c-myc 
promoter (47) in vivo and in vitro, in both linear and super-coiled plasmid forms 
(48).  Upon further characterization of the nucleolytic activity of H1, it appeared 
that the H1-dependent cleavage of DNA exhibited marked differences from that 
of H2.  The H2 molecule consistently generates internal cuts of double stranded 
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DNA indicative of an endonuclease, while H1 catalyzed the removal of individual 
nucleotides progressively from the 3’ terminus of single-stranded 
oligodeoxynucleotides in the 5’ direction (43, 49).  Additional evidence of 
nuclease activity has been reported for the E. coli homolog ndk (50), along with a 
previously undescribed role in genomic maintenance (34), suggesting 
evolutionary conservation for this function in addition to ndpk, and underscoring 
the importance of this activity.  The contribution of the nuclease function to H1-
mediated metastasis suppression is still unclear, however, recent studies have 
begun to shed light on the necessity for this activity, as well as ndpk, in 
supporting NM23-dependent genomic integrity and metastasis inhibition (32, 35). 
  
Identification of the multiple biochemical activities of H1 has provided 
valuable mechanistic insight into this NM23 isoform and its roles within the cell, 
expanding the realm of possibilities for mechanisms of H1-dependent metastasis 
suppression.  The advent of high-throughput global proteome and gene 
expression analyses should facilitate discovery, as perhaps the most promise for 
finally understanding how H1 may mediate metastasis suppression will arise from 
the identification of gene products with which NM23 demonstrates a physical 
interaction and/or regulates their expression.  Over the last decade, H1 has been 
shown to bind a variety of proteins, a number of which are components of 
complex intracellular signaling networks.  Some examples are Rad (51), Tiam1 
(52), EBNA-3C (53), KSR (38), CDC42 (54), Dbl-1 (55) and Prune (56).  The 
physiological effects of these interactions are variable ranging from regulation of 
transcription to endocytosis, as well as modulation of MAPK signaling.  Should 
H1 contribute to maintenance of proper signal transduction, the loss of 
expression could very easily lead to profound biological consequences.  Tight 
regulation of signaling networks is crucial for cellular homeostasis and the 
disruption of critical protein complexes and networks used to transmit information 
resulting from genetic mutations, amplifications, etc., can have significant 
deleterious effects on the cell.  In fact, several key genetic components of broad 
signaling networks are synonymous with cancer and metastasis including Ras, 
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AKT, and Wnt. The subsequent deregulation of these gene products is 
commonly found to be the driving force in tumorigenesis and progression.   
The MAPK pathway in particular has been a functional target of the H1 
molecule according to reports of interactions with gene products Rad, Tiam1 and 
KSR.  MAP kinases have multiple roles in growth, differentiation and survival 
while also promoting cancer progression in many instances (57-59).  Significant 
contributions are thought to be made by MAPK pathway components to not only 
proliferation, but also proteolytic degradation of extracellular matrix, invasion, 
motility and metastasis.  Three main branches of MAPK signaling are thought to 
exist mediated through extracellular signal-regulated kinase 1/2 (ERK 1/2), c-Jun 
N-terminal kinase/stress-activated protein kinase (JNK/SAPK), and p38 (60).  
These networks have been extensively characterized and play specific roles 
within the cell, mediated by chains of different signaling isoforms and scaffolding 
molecules to direct information-rich phosphorylation of conserved tyrosine and 
threonine residues.  While usually depicted as linear networks, it is known that a 
large amount of cross-talk occurs within these pathways, increasing complexity 
but also specificity of signals to generate the desired cellular response (Figure 
1.2). 
With reports of Ras/MAPK-mediated stimulation of cell motility (61, 62), it 
should be noted that migration was found to be commonly impacted following the 
interaction of H1 with a number of these different proteins.  This suggests that H1 
is incorporated with signaling mechanisms that perhaps underlie the phenotypic 
response, e.g., suppressing migration and/or invasion.  It is understood that 
these signaling pathways typically induce some level of differential gene 
expression as the endpoint response of the cascade.  As a result, microarray 
analyses following H1 overexpression in a number of different systems have also 
been utilized as a tool for investigating how NM23 is able to suppress metastasis, 
identifying a myriad of genes which may contribute to H1-mediated suppression 
(63-67).  For example, discovery of H1-dependent reductions to transcript levels 
for the lysophosphatidic acid (LPA) receptor, EDG2, in metastatic breast cancer 
cells demonstrates yet another level of influence H1 exhibits upon the conduction  
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Figure 1.2 Mitogen Activated Protein Kinase (MAPK) Signaling in Mammals 
(adapted from (60)).  The three main branches of the MAPK cascade are 
depicted and expected phenotypic outcomes displayed.  The majority of 
information has linked H1 to the network propagated through the Raf molecule 
(far left) and as noted, this arm of the pathway has been implicated in metastasis. 
Therefore, the Raf-MEK-ERK pathway seems to be an important target for 
induction of H1-mediated motility and metastasis suppression.  
 
 
 
 
 
 
 
 
NM23-H1 
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of critical cellular signaling events (64).  Collectively, this data would suggest that 
H1 has a much more global impact on the signaling repertoire than perhaps 
initially appreciated and this regulation may contribute significantly to the 
negative regulation of metastasis. 
 
In Vitro Correlates of Metastasis 
The clinical promise of targeting metastasis is based on the principle that 
preventing just one aspect of the cascade can render a cell incapable of 
successful metastasis, suggesting a multitude of novel approaches could be 
effective.  Achievement has proven difficult however, as treatments aimed 
specifically at the metastatic process have shown little clinical success (68), 
encouraging the need for further molecular research.  It is generally accepted 
that in vivo models must be used to adequately study metastasis but this 
approach can be costly, time-consuming, and make it difficult to interpret due to a 
lack of mechanistic information.  However, improvements have been made with 
recent advancements to in vivo imaging techniques, as a recent report has 
shown the use of laser-scanning microscopy is making it possible to monitor 
cancer cell dissemination within a live organism (69).  While far superior to 
equipment of the past, access to facilities with such capabilities is just now 
becoming realistic options for many researchers.  Such drawbacks, along with 
the relative ease in which cell culture assays are conducted, has prompted the 
use of in vitro systems to study the many aspects of metastatic spread.  
Generally, in vitro assays have been designed to recapitulate the individual steps 
or components of the cascade.  For example, common indicators of metastatic 
potential in vitro are motility, invasiveness and ability to colonize in soft agar.  
Though many techniques are available to assess these traits, there is not an in 
vitro cell culture model that can accurately mimic all of the environmental factors 
relevant in vivo at once.  Nonetheless, when used to complement animal studies, 
these types of assays can be extremely informative but still cannot stand alone 
as comprehensive.   
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The use of such culture systems to study the cellular response to H1 has 
indicated that the enzyme influences a number of aspects of cell fate and 
behavior, any of which could contribute to the suppression of metastasis.  H1-
dependent effects on motility/invasion inhibition (70, 71), anchorage-independent 
growth (29, 31), angiogenesis (72), and promotion of differentiation (73) or cell 
death (74-76) are common, although for the most part, concise descriptions for 
mechanisms of action have been lacking.  Descriptions of molecular events that 
lead to a particular phenotype could greatly benefit from the identification of the 
inherent enzymatic functions necessary for mediating H1-dependent effects.  
Site-directed mutagenesis experiments have effectively linked the histidine 
kinase function of H1 to motility suppression and inhibition of metastasis in breast 
carcinoma cell lines (37, 42), as previously mentioned due to its interaction with 
the kinase suppressor of ras (KSR).  The sites of phosphorylation on KSR were 
identified as serine residues 392 and 434 which alter the scaffolding properties of 
KSR and consequently disrupt Ras-initiated MEK signal propagation and cellular 
motility in MDA-MB-435 and 293T cells (38, 77).  Further investigation using site-
directed mutagenesis should continue to facilitate the elucidation of the individual 
activities of H1 and assess the impact of each one in a variety of cellular 
contexts.  
Although mutagenesis has proven useful in dissecting its enzymatic 
activities, naturally occurring mutations in the H1 gene product are rare.  While it 
is quite common to find genetic or epigenetic mutations of tumor suppressor 
genes driving oncogenesis (e.g., p53, PTEN, RB, etc.), loss of NM23-H1 
generally results from reduced expression and not from inactivating mutations 
(17).  Spontaneous mutations to the NM23-H1 gene in humans have only been 
found in several cases of high-grade neuroblastoma, where Ser120 is replaced 
with a glycine residue and overexpression is positively correlated with 
aggressiveness of the disease (78).  This mutated gene product is characterized 
by abnormal structure due to improper folding and fails to confer motility 
suppression and prevent soft agar colonization in MDA-MB-435 cells in vitro 
when compared to the wild-type molecule (37, 79).  Another naturally-occurring 
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amino acid substitution identified is a serine substitution of the Pro97 residue in 
the awd gene, the homolog of NM23 in Drosophila melanogaster, was shown to 
be a conditional dominant mutation known as Killer of prune (Kpn) (80).  Unlike 
S120G, this mutation was not initially linked to cancer and was originally shown to 
impair development in fruit flies (80-82).  Interestingly, both S120G and P96S are 
reportedly unable to confer metastasis suppression to malignant breast 
carcinoma cells due to the loss of histidine kinase activity (36, 41).  As a result, 
quite a bit of interest has been shown in these mutants resulting in extensive 
characterization of their impact on cell biology in a number of models (40, 83-86). 
Nonetheless, structure-function analyses of a variety of specific mutants have 
identified individual residues necessary for the multiple activities of the H1 
molecule (Table 1.1), allowing for partial mapping of respective active sites and 
the study of each function in isolation.  It has been shown that both kinase 
activities require the catalytic His118 residue (32, 87), with residues Lys12, Tyr52, 
Arg88, Pro96 and Asn115 also being reported to facilitate ndpk activity (43, 88, 89). 
The histidine kinase function is dependent upon Lys12 and Pro96 as well, along 
with Ser120 (37), while the 3’-5’ exonuclease necessitates residues Lys12 and Glu5 
(43, 90).  A Q17N mutant was also characterized for the H2 isoform where it 
disrupted the nuclease activity without negatively affecting ndpk (88).  While 
these investigations have uncovered quite a bit about the molecule, complete 
characterization of all three activities in any mutant prior to the report herein have 
been lacking.   
In addition to in vitro characterization of recombinant proteins, forced 
expression of the wild-type (WT) and mutant forms of NM23 in metastatic cell 
lines devoid of endogenous H1 expression has provided important evidence into 
how these functions may relate to H1-mediated metastasis suppression.  As 
mentioned, the strongest case made to date for a mechanism of H1-dependent 
antimetastatic function is via motility suppression in aggressive cell lines. Without 
question, the ability of a tumor cell to invade and move through the stroma is a 
necessity for metastatic spread, specifically for intravasation and extravasation, 
two rate limiting steps in metastasis.  While NM23 is unequivocally linked to  
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Table 1.1 Amino Acid Residues Reportedly Necessary for Appropriate 
Enzymatic Function of H1 
 
Nucleoside 
diphosphate kinase 
(ndpk) 
Histidine-
dependent protein 
kinase 
3’-5’ exonuclease 
Amino acid 
residues 
K12 
Y52 
R88 
N115 
H118 
K12 
P96 
H118 
S120 
E5 
K12 
F33 
D54 
D121 
E129 
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motility suppression, various mechanisms have been proposed, from its 
transcriptional regulation of EDG2 (64), to a direct interaction and regulation of 
the cytoskeletal machinery (e.g. Cdc42) (54) making it difficult to accept a single 
mechanism as the pathway through which H1 is acting.  Forced expression of 
wild-type and mutant forms of H1 continues to be an attractive model for 
gathering mechanistic information concerning H1 biology and should help resolve 
some of the confusion surrounding its actions. 
 
Melanoma Progression and NM23 
 One of the main goals of this study was to better understand the role of H1 
in tumor progression.  In solid tumors, this is a daunting task as it is difficult to 
identify the relatively few aggressive cells within a heterogeneous primary lesion 
that are programmed for clonal expansion and metastasis.  However, in the 
context of melanoma, development is typically thought to follow a step-wise 
progression with distinct phenotypic changes associated with increasing levels of 
aggressiveness (Figure 1.3).  Most melanomas arise from a benign nevus 
following some type of genetic insult (e.g., UV irradiation) that eventually 
progresses to a radial growth phase (RGP) melanoma.  RGP melanoma is 
classified as a lesion that spreads superficially, confined within the epidermis, 
outward from the center of the growth and showing no tendency for rapid growth 
or metastatic ability (91).  Events not completely understood then trigger a 
phenotypic shift which permits the cancer to grow vertically down into the dermis 
and subcutaneous tissue (vertical growth phase; VGP), creating a route for highly 
aggressive tumor cells to breach blood or lymphatic vessels and spread 
throughout the body enabling the progression to metastasis. 
In cancer, accumulating genetic or epigenetic mutations to key oncogenes 
or tumor suppressors drives tumorigenic transformation and a few specific 
aberrancies have been linked specifically to melanoma.  Examples include 
amplification of genes such as KIT, MITF, TBX2 and MYC or activating mutations 
in others as seen with BRAF, NRAS and -catenin (92).  Mounting evidence is 
suggesting that many of these anomalies are impacting proliferative, senescence 
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Figure 1.3 Development and Progression of Melanoma.  Based on a model 
proposed by Clark, Elder and Guerry (93, 94), the schematic depicts the 
sequential steps of melanoma progression.  The driving forces behind the 
transition from one phase to another have not been completely elucidated.  Each 
group is histopathologically distinct with the radial growth phase representing the 
first recognizable malignant stage.  Evidence of spontaneous regression exists 
for non-tumorigenic lesions albeit through unknown mechanisms. 
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or cell death pathways in melanoma, conferring survival advantages to the tumor 
cells and rapidly expanding the likelihood of clonal outgrowth of metastases.  It is 
obvious that certain groups of these genes must be altered independently of one 
another as many genes are not found to be mutated within the same lesion, while 
others may be promoting cancer progression.  For example, activating mutations 
to NRAS and BRAF both play significant roles in the pathogenesis of melanoma 
however, these lesions have never been observed concurrently in melanoma 
indicating that this combination has a negative effect on clonal selection (95).  
While the exact reason for this is unknown, it has been suggested that cells 
harboring this combination of mutations could be overstimulated, causing 
catastrophic effects to the cells (92).  Other combinations of genetic mutations 
actually facilitate the disease likely by disabling mechanisms which act as 
inherent safeguards against oncogenesis, as seen with the matched cohort of 
melanoma cells used in the studies presented herein.  While both VGP WM793 
melanoma cells and metastatically derived 1205LU cells harbor an activating 
mutation to the BRAF gene, only the 1205LU cells have acquired inactivating 
mutations to the tumor suppressor PTEN, showing this gene most likely has a 
role in preventing malignant progression in this system.  Additional evidence to 
support this concept has been shown using normal melanocytes engineered to 
overexpress BRAF, which senesce when grown in culture due to overstimulation 
of the MAPK cascade (96, 97).  Therefore, propagation of a melanoma depends 
on the selection of cancerous cells that respond to hyperproliferative signals and 
are able to overcome cell death or senescence, appearing refractory to 
endogenous safeguards used to maintain normal cellular homeostasis.  
Although the NM23-H1 gene has been shown to consistently suppress 
metastasis in melanoma cells, a clear picture of the way in which it is achieving 
this effect has yet to emerge.  Understanding the events which lead to the 
formation of a melanoma and ultimately metastasis has helped focus new 
hypotheses on the most likely areas being impacted by H1.  As our interest has 
shifted to its role within the primary tumor, the biology outlined above would raise 
the possibility that H1 is somehow helping to reconstruct or maintain a means of 
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protection within the system that would prevent the expansion of the most 
aberrant and aggressive cells.  However, other specific aspects of suppression 
have been generally accepted as the significant contributing factor to H1-
mediated prevention of metastasis, the most popular of which are reductions in 
cell motility and anchorage-independent growth.  A problem arises though as the 
extent of interdependence between motility, invasion and contact-inhibited 
growth with other processes known to prevent melanoma progression, such as 
genomic instability, has yet to be elucidated.  The conundrum then becomes 
determining how H1 is driving these effects, by individually blocking aspects of 
motility, invasion or growth in soft agar, or perhaps by controlling a host of factors 
or even a genetic program that culminates in the observed phenotype.  Recent 
evidence would suggest that the impact of H1 on key signaling pathways 
controlling a host of biological outcomes is a plausible scenario for mediating 
these effects.  As a result, the conclusions drawn from some models of NM23-
dependent metastasis suppression generally accepted within the field may be 
oversimplified and misleading.    
 
Hypothesis 
The multiple enzymatic functions of NM23-H1 individually influence the 
expression of specific genetic programs culminating in decreased motility, 
invasion and metastatic potential of melanoma cells. 
 
Project Objective 
As we have come to discover the existence of multiple properties inherent 
to H1, identifying the contributions of each activity in suppressing metastasis has 
become the focus of a number of studies including many of our own.  The focus 
of my dissertation research has been on the discovery of non-functional mutants 
of the H1 molecule and characterizing their biological effects in a cohort of 
melanoma cells.  The first part of the study was composed of structure-function 
analyses of recombinant H1 proteins, identifying amino acid residues necessary 
for mediating each of the three known enzymatic activities of NM23.  This was 
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followed by investigation of stable cell lines overexpressing mutant and wild-type 
H1, characterizing their relative capacities for motility and invasion in cell culture 
systems.  Gene expression array analysis was also used in hopes of identifying 
H1-regulated gene targets responsible for the observed phenotypes.  With the 
identification of novel genes that were regulated by H1 and tracked with motility 
suppression in this system, the use of RNA interference allowed for the 
manipulation of target genes in order to assess the contribution of differential 
gene expression patterns on cell motility.  Ultimately, two genes in particular, 
BRAP and IQGAP2, were found to mediate the motile phenotype observed in 
WM793, VGP melanoma cells.  These two genes have been linked to the 
oncogenic Ras signaling cascade, bringing to light a potential novel role for H1 in 
regulating this pathway.  In addition, these findings stongly implicate H1-
dependent manipulation of gene expression patterns as a means of conferring 
motility suppression and, more than likely NM23-mediated metastasis 
suppression as well.  
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CHAPTER TWO 
 
NM23-H1-mediated Suppression of Motility and Invasion in Metastatic 
Melanoma Cells Acts Independently of its Known Enzymatic Activities1 
 
Introduction 
The identification of the multiple functions of H1 was achieved mainly 
through the demonstration of these activities in vitro.  The use of site-directed 
mutagenesis was a fundamental component of these discoveries as recombinant 
proteins were expressed and purified from E. coli in order to examine the effects 
of specific amino acid substitutions on normal function.  Prior to starting the 
current study, our initial characterization of mutations disrupting kinase and 
exonuclease activity (Lys12) originally described for the H2 isoform (89), while 
confirming the requirement of His118 for proper kinase function (43), had been 
reported (30).  The goal was then to identify a selective lesion that hindered 
exonuclease activity in addition to fully characterizing all mutants of interest in the 
context of the three known functions, a feat yet to be completed by any other labs 
to this point. 
A report published in 2005 was the first to implicate amino acid residues 
E5 and D54 as being required for H1-mediated exonuclease activity (90).  To 
validate that these selective lesions disrupt this function exclusively, the E5A and 
D54A substitution mutants were tested for their ability to cleave a single-stranded 
DNA substrate.  While recombinant preparations of the H1 mutant D54A showed 
nuclease activity similar to the wild-type enzyme (data not shown), the E5A 
mutant showed >85% reduction in the amount of substrate degraded.  
Completion of the functional analysis confirmed that the E5A mutation exhibited 
the desired phenotype as this particular mutation was disruptive to exonuclease 
function only while having little impact on the kinase activities.  This was a highly 
sought-after, missing piece of a model which would be used to delineate the 
                                                          
1
 Results published previously: Q Zhang*, JR McCorkle*, et al. Int J Can, 2010 
* Authors contributed equally to this work 
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importance of the individual enzymatic activities of H1 on its ability to suppress 
metastasis, providing the basis for all subsequent experiments discussed herein.  
Testing the biological effects of this collection of specific H1 mutants in a 
cellular context was achieved using a metastatic melanoma cell line, 1205LU.  
Stable transfectants of NM23-H1 wild-type (WT) and mutant variants were 
compared based on in vitro motility and invasive capacity as well as proliferation 
rates.  While H1-WT clearly suppresses migration and invasion in this aggressive 
cell type, an inherent enzymatic function of H1 responsible for mediating this 
phenotype, including the histidine kinase function, could not be conclusively 
established.  This raises the possibility that H1 is blocking cellular movement 
through a novel pathway in metastatic melanoma and not via its histidine kinase 
activity as has been reported (40, 41).  Additionally, the kinase functions of H1 
were not able to be separated by any of the mutations tested. With His118 being 
the phosphorylated residue in both kinase reactions, it would appear that a 
mutation impacting this residue should also cause loss of motility suppressive 
capacity if mediated by a histidine kinase mechanism.  However, similar to the 
observed results in this system using 1205LU cells, H118F conferred full 
suppression of invasion on cells derived from human prostate carcinoma (31).  
Further investigation into any link between a histidine kinase function and motility 
or metastasis suppression requires increased attention in the future to determine 
if indeed this activity is important for blocking cell motility and/or invasion.         
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Materials and Methods 
Site-directed Mutagenesis and Expression Vectors:  Mutant constructs for 
variants of NM23-H1 were produced as described either through the use of 
overlap extension modifications of the polymerase chain reaction (98) (P96S) or 
the QuikChange site-directed mutagenesis kit (E5A) (Stratagene, La Jolla, CA).  
E. coli expression vector pET3c (New England Biolabs, Ipswich, MA) was used 
for generation of recombinant proteins and were created with the insertion of 
mutant cDNA molecules between NdeI and BamHI restriction sites.  H1-wild-type 
and H118F plasmids were kind gifts of Dr. E. Postel (U. of Medicine and Dentistry 
of New Jersey, New Brunswick, NJ); K12Q construction was previously described 
(43).  Mammalian expression vectors were produced in a similar manner, 
inserting cDNAs into pCI-EGFP plasmids driven by a cytomegalovirus (CMV)-
promoter and containing an internal ribosome entry sequence (IRES) for 
coexpression of enhanced green fluorescent protein (EGFP).  The pSV2neo 
(Clontech, Mountain View, CA) vector facilitated the selection of stable 
transfectants by conferring resistance to Geneticin (neomycin analog, G418; 
Clontech).  
 
Size-exclusion HPLC and circular dichroism analyses:  Purified wild-type or 
mutant forms of recombinant NM23-H1 were analyzed using the Shodex gel-
filtration KW-800 high-performance liquid chromatography (HPLC) column 
(Showa Denko, New York, NY), pre-equilibrated in 50 mM Tris-HCl pH 7.5, 0.1 M 
KCl.  Molecular weight estimates were generated using gel filtration molecular 
weight standard kit ranging from 12 - 200 kDa (Sigma, St. Louis, MO).  Circular 
dichroism analyses were conducted as previously described (43) using a Jasco-
810 spectrometer.  Secondary structure estimates were derived from the 250-
190 nm region of the recorded spectra using CONTILL, SELCON3, and CDSSTR 
applications (99) found in the CDPro Software package 
(http://lamar.colostate.edu/∼sreeram/CDPro). 
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Nucleoside diphosphate kinase (ndpk) assays:  Ndpk activity was measured as 
described (27) and adapted for use in a 96-well plate reader (43).  Wild-type and 
mutant recombinant H1 was tested for its ability to generate ADP in the presence 
of ATP and dTDP in a coupled pyruvate-lactate dehydrogenase assay.  Purified 
H1 was added to the bottom of the wells in 10 L aliquots (in 20 mM Hepes pH 
7.9) followed by the addition of a 140 L reaction mixture resulting in final 
concentrations of 0.42 mM -NADH, 1 mM phosphoenolpyruvate, 5 mM ATP, 2.5 
mM dTDP, 6 mM MgCl2, 50 mM KCl, 100 U each of pyruvate kinase and lactate 
dehydrogenase.  Oxidation of NADH was measured at 340 nm every 15 seconds 
over a 3 minute time period.  Specific activity is expressed as units/mg of protein 
with 1 unit defined as the amount of enzyme necessary to convert 1 mol of 
ADP/minute at room temperature (  of NADH = 6.22 x 103 M-1 cm-1). 
 
Histidine-dependent protein kinase assays:  Histidine kinase activity was 
measured as originally described (37) with slight modifications (32).  [ -32P] ATP 
(3000 Ci/mmol; Perkin Elmer, Waltham, MA) was diluted with unlabeled 10 mM 
ATP lithium salt to a specific activity of 50 Ci/mmol.  20 g of purified H1 was 
incubated with 500 Ci [ -32P] ATP for 15 minutes at room temperature to allow 
for autophosphorylation.  Reactions took place in 100 l of 20 mM Tris-HCl, pH 
8.0, 5 mM MgCl2 and 1 mM dithiothreitol (DTT).  Samples were cleared with 
centrifugal filtration at 4o C to remove unbound ATP.  Autophosphorylated H1 (2 
x 105 cpm) was combined with a 5-fold molar excess of purified recombinant 
NM23-H2 in a 30 L reaction mixture of 20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 
5 mM MgCl2, and 1 mM DTT.  Reactions were stopped using room-temperature 
SDS sample buffer followed by electrophoresis on 13% SDS-PAGE gels.  Gels 
were dried under vacuum at 80o C followed by visualization with 
phosphorimaging using a STORM840 (Amersham Biosciences, Piscataway, NJ).  
Pixel intensities were measured with ImageQuant software (Amersham 
Biosciences). 
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3’-5’ exonuclease assays:  Activity was measured using a 33-base 
oligodeoxyribonucleotide substrate derived from a sequence found within the 
non-coding strand of the 5’SHS silencer region of the platelet-derived growth 
factor-alpha (PDGF-A) gene (100), as previously described (49).  Radiolabeling 
of the 5’-termini was conducted with [ -32P]ATP and T4 polynucleotide kinase 
(Roche, Nutley, NJ) and efficiency of labeling was determined using non-
denaturing polyacrylamide gel electrophoresis.  Purified radiolabeled substrates 
(10-20 fmols) were incubated with purified recombinant H1 (0.5 g) at room 
temperature in a 15 l mixture containing 20 mM HEPES buffer (pH 7.9), 2 mM 
MgCl2, and 100 mM KCl.  Samples were resolved on 20% sequencing gels and 
visualized with phosphorimaging (STORM840, Amersham Biosciences). 
 
Cell lines, culture & stable transfection:  The metastatic melanoma cell line, 
1205LU was a generous gift of Dr. M. Herlyn (Wistar Institute, Philadelphia, PA).  
Cells were maintained under 5% CO2, 37
o C in TU 2% growth medium composed 
of MCDB153: Leibovitz-15 (4: 1; v: v) (Sigma, St. Louis, MO: Gibco, Carlsbad, 
CA) with 2 mM CaCl2 (Fisher Scientific, Pittsburgh, PA), 5 g/mL insulin (Sigma, 
St. Louis) and 2% fetal bovine serum (FBS) (Gibco).  Stable transfectants were 
generated previously by Dr. Q. Zhang (University of Chicago, Chicago, IL) in our 
lab as described (32).  Briefly, pCI-EGFP based expression vectors along with a 
pSV2-neo plasmid (both kind gifts of Dr. S. Kraner, U. of Kentucky) were co-
transfected at a ratio of 1:0.3 g, delivered using Fugene 6 liposomal reagent 
(Roche, Nutley, NJ).  Forty-eight hours following transfection, cells were exposed 
to growth media supplemented with 250 g/mL of G418 for 3 weeks.  Cells 
surviving the selection period were then subjected to fluorescence-activated cell 
sorting (FACS; FACSCalibur Flow Cytometer, Becton-Dickinson, Mountain View, 
CA) to obtain a mixed population of stable transfectants. 
 
Cell Proliferation Assays:  1205LU parent and stable transfected cell lines were 
seeded 1x104 cells/well in 96-well plates and grown under normal growth 
conditions.  Relative growth rates were assessed every 24 hours for 5 days using 
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CellTiter 96 AQueous Non-radioactive Cell Proliferation Assay (MTS) (Promega, 
Madison, WI) according to the supplied protocol.  Each cell line was measured in 
at least 5 replicate wells per experiment and results reflect a minimum of 3 
independent experiments. 
 
Transwell Cell Motility and Invasion Assays:  Cell motility was monitored with 
Transwell chambers (24-well, 8.0 m pore) (Corning, Lowell, MA) while cell 
invasion was determined with BioCoat Matrigel Invasion Chambers (24-well, 8.0 
m pore) (BD Biosciences, San Jose, CA).  Rehydration of the membranes for 
invasion studies was achieved according to protocol in protein-free TU (insulin- 
and FBS-free) melanoma cell culture media for 2 hours at 5% CO2, 37
o C.  For 
both motility and invasion assays, 1205LU cells were then seeded 1x104 in the 
upper chamber in TU growth media supplemented with 0.1% FBS and 0.25 
g/mL insulin.  The lower chamber was filled with normal TU 2% culture media 
(2% FBS and 5 g/mL insulin) and cells were kept for 20-22 hours at 5% CO2, 
37o C.  Cells remaining in the upper compartment were then washed twice with 
phosphate-buffered saline (PBS, pH 7.4) and non-motile/invading cells were 
removed using a cotton swab.  Cells attached to the underside of the membrane 
facing the lower chamber were fixed for 10 minutes at room temperature in 100% 
methanol, followed by three washes in PBS and staining for 1 hour in Gill’s 
hematoxylin #2 (Vector Laboratories, Burlingame, CA).  Membranes were 
extensively washed then allowed to dry overnight at room temperature.  Stained 
cells were counted in 5 non-overlapping, random fields per membrane using light 
microscopy (10 x 10 magnification).  Results are from at least 3 experiments with 
a minimum of 3 replicate wells each.   
 
Immunoblot analysis:  Whole cell lysates were prepared from near-confluent 
cultures using a modified RIPA lysis buffer (10 mM sodium phosphate, pH 7.2; 
150 mM sodium chloride; 0.1% sodium dodecyl sulfate; 1% sodium 
deoxycholate; 1% Triton X-100; 50 mM sodium fluoride; 2 mM EDTA, pH 8.0; 
with freshly added sodium vanadate (0.2 mM), and 1 g/mL each of pepstatin A 
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and leupeptin).  Quantitation of protein concentration was achieved with Bradford 
microplate assays (Bio-Rad, Richmond, CA) measuring 620 nm absorbance and 
using -globulin for generation of a standard curve.  Fifty micrograms of extract 
was separated on 15% SDS-PAGE gels under reducing conditions, followed by 
transfer to nitrocellulose membranes (0.4 m pore size; Bio-Rad) in the presence 
of 20% methanol.  Primary and secondary antibody incubations occurred for 1 
hour at room-temperature.  Species specific secondary antibodies used were 
conjugated with horseradish-peroxidase (GE Biosciences, Piscataway, NJ) and 
signals were generated following incubation for 5 minutes in ECL Plus Western 
Blot Detection Reagent (GE Biosciences) and detected with X-ray film (Eastman 
Kodak Co., Rochester, NY).  Primary antibodies used included a mouse 
monoclonal anti-NM23 (BD Biosciences, San Jose, CA) and anti- -tubulin (Santa 
Cruz Biotechnology, Santa Cruz, CA). 
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Results 
In vitro Characterization of Wild-type and Mutant Variants of H1 
As with the previous report describing mutants H118F and K12Q (43), 
recombinant H1 molecules, in wild-type and mutant form, were bacterially 
expressed and purified to near homogeneity.  Structural defects were then 
assessed using circular dichroism (CD) spectrometry and size-exclusion HPLC 
gel filtration, enabling the identification of amino acid residues directly necessary 
for proper enzymatic activity and ruling out disruption of secondary or oligomeric 
conformation as cause for the loss of function.  CD analysis showed molar 
ellipticities similar to the wild-type molecule suggesting that the amino acid 
substitutions E5A, Y52A and P96S did not significantly alter the secondary 
structure of H1 (Figure 2.1).  On the other hand, the Q17N mutant did in fact 
exhibit some significantly different secondary structures, specifically, a reduction 
in -helix content.  In addition, proper oligomerization was confirmed using gel 
filtration HPLC showing molecular weight estimates of mutants and wild-type H1 
were not statistically different from one another, except for the Y52A variant 
(Table 2.1).  The anomalies in structural properties of the Y52A and Q17N mutants 
prompted the discontinuation of their use in further downstream studies to 
investigate their effects in cancer cells based on the inability to conclusively link 
function to amino acid residues.  Nonetheless, these results confirmed 
successful targeting of amino acid residues by site-directed mutagenesis which 
do not significantly disrupt protein stability and are possibly mediating the 
observed physiology of the molecule. 
While P96S and E5A had already been shown to impair histidine kinase 
and 3’-5’ exonuclease function respectively (37, 90), the complete 
characterization of these two mutants, as well as H118F and K12Q, in respect to all 
three activities had yet to be demonstrated.  Assessment of histidine kinase 
function revealed a necessity for residues H118, K12, Y52 and to a lesser extent 
P96, with the E5A and Q17N mutants displaying relatively normal activity (Figure 
2.2).  Interestingly, a very similar result was observed for the ndpk functions and 
the impact of the amino acid substitutions disrupting this function mirrored that of  
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Figure 2.1 Circular Dichroism Spectrum for NM23-H1 Variants.  Circular 
dichroism spectrometry was used to compare secondary structure of wild-type 
and mutated recombinant H1.  Bacterially expressed (E. coli) recombinant 
preparations of wild-type, E5A, Q17N, Y52A and P96S were purified to 
homogeneity prior to analysis.  Mutants K12Q, R34A and H118F were tested and 
described in a previous study (43).  
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 Table 2.1 Molecular Weight and Secondary Structure Estimates of NM23- 
 H1 Variants1   
Protein 
Molecular 
Weight (kDa)2 
CD spectrometry3 
-helix -sheet Turns Random 
WT 87.7 ± 2.1 14.2 ± 2.8 32.6 ± 5.3 20.0 ± 0.1 32.6 ± 3.8 
E5A 85.1 ± 7.1 
10.7 ± 2.2 35.0 ± 2.5 19.4 ± 0.6 32.9 ± 1.8 
Q17N 86.3 ± 1.5 
8.8 ± 2.6 40.2 ± 4.3 18.7 ± 2.0 32.3 ± 0.7 
Y52A   78.4 ± 3.0* 
11.4 ± 4.1 35.9 ± 1.9 19.4 ± 1.4 30.7 ± 1.1 
P96S      84.7 ± 0.4 
13.7 ± 1.7 33.0 ± 1.2 19.8 ± 1.3 32.7 ± 2.0 
1Estimates for mutants K12Q and H118F published previously (43).  
2Results are   
expressed as means ± standard deviation from 3 replicate measurements on 3 
independent protein preparations. 3Secondary structures are expressed as a 
percentage of the total structure content (Mean ± standard deviation).  *Mean 
value is significantly different (One-way ANOVA, p ≤ 0.05). 
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Figure 2.2 Characterization of Exonuclease Activity for the E5A Mutant.  
Purified preparations of recombinant NM23-H1 (500 ng) were incubated at room 
temperature with 5’-radiolabeled single-stranded DNA oligonucleotide substrate 
(10 fmol) for the indicated times.  Cleavage products were resolved on 20% 
polyacrylamide sequencing gels, dried under vacuum and visualized by 
phosphorimaging.  Results for mutants K12Q, H118F and P96S were published 
previously (32, 43). 
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the histidine kinase activity (Table 2.2).  With respect to the exonuclease, loss of 
function was observed with the E5A and K12Q mutants while P96S and H118F 
displayed no statistical difference from wild-type in regards to nucleolytic activity 
(Figure 2.3b; Table 2.2).  This allowed us to separate the mutants into groups 
based on enzymatic aberrancies.  These include mutants selectively deficient in 
exonuclease activity (E5A), tandemly-deficient in both kinase activities (P96S, 
H118F) and completely devoid of all three functions (K12Q).  This panel of mutants 
permits the examination of the contribution(s) of the components of the 
enzymatic repertoire of H1, individually and collectively, on metastasis-relevant 
cellular physiology and ultimately, suppression of disease progression. 
NM23-H1 Overexpression in 1205LU Metastatic Melanoma Cells       
Stable transfectants of the human melanoma cell line 1205LU were 
generated for the wild-type form of H1, along with mutants E5A, K12Q, P96S and 
H118F.  These cells are metastatic in athymic nude mice (101) and display low 
endogenous expression of NM23-H1 and H2.  Stable transfectants 
overexpressing NM23-H1 were genereated and subjected to antibiotic selection 
and flow-cytometry to isolate co-expressing EGFP-positive cells.  Transfectants 
were then pooled to generate the working populations of stable cell lines used for 
downstream analyses.   
As expected with a metastasis suppressor protein, elevated levels of H1 
had no bearing on the in vitro proliferation rates of these cells (Figure 2.4), an 
observation that was also seen when grown as tumor explants in athymic nude 
mice using the same cell lines (32).  Wild-type H1 overexpression has 
consistently reduced motility and invasion in a number of metastatic cell lines. 
While not surprising, the data presented here show 1205LU cells also exhibit 
similar reductions upon forced expression of H1, a novel finding for this particular 
line (Figure 2.5).  The impact of the mutations of interest in blocking motility and 
invasion in these cells however was completely unexpected as all mutant cell 
lines showed full suppression in this system.  This is in conflict with previous 
reports suggesting that the P96S mutant lacks the ability to impede motility and 
invasion in cell lines derived from metastatic breast carcinoma and large cell lung 
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Table 2.2 Molecular Functions of NM23-H1 variants 
Protein NDPK1 Histidine kinase2 3’-5’ Exonuclease3 
Wild-type  627 ± 36a (100) 9.9 (100)       28.4 ± 4.0 (100) 
E5A      438 ± 31
b (70) 8.2 (83)         3.4 ± 1.5* (12) 
K12Q 14 ± 0.9
c (2) 0.9 (9)         5.2 ± 3.5* (18) 
Q17N      516 ±10
b (82) 6.5 (66)       31.4 ± 6.0 (110) 
Y52A            B.D. 0.4 (4)       25.3 ± 3.9 (89) 
P96S      127 ± 5
d (20) 1.1 (11)       24.9 ± 5.1 (88) 
H118F            B.D. B.D.       33.0 ± 9.0 (116) 
B.D.: below detection (< 5 units/mg). 1NDPK activity is expressed as units/mg 
(mean ± standard error) derived from at least 3 replicate measurements from 3 
independent protein preparations. Percentage of wild-type activity is shown in 
parentheses.  2Histidine kinase activity is expressed as the percent conversion of 
a NM23-H2 substrate to phosphorylated form per minute.  3Exonuclease activity 
is shown as fmol of nucleotides removed from a 32P-radiolabeled substrate per 5 
minutes (mean ± s.e.) as determined from replicate measurements from at least 
3 independent protein preparations.  *Means within a column are significantly 
different (p ≤ 0.05) as determined by student’s t-test. a-eMeans not bearing a 
common superscript are significantly different (p ≤ 0.01) as determined with the 
student’s t-test. 
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Figure 2.3 Analysis of Histidine Kinase Activity Among H1 Variants.  
Recombinant NM23-H1 proteins were autoradiolabeled with [ -32P] ATP, followed 
by removal of unbound ATP using centrifugal filtration.  Labeled H1 was 
incubated in the presence of 5-fold molar excess of unlabeled recombinant 
NM23-H2 for the times indicated.  Reaction products were resolved using SDS-
PAGE and images acquired with autoradiography. 
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Figure 2.4 Cell Proliferation Rates of 1205LU Stable Transfectants in vitro.  
(A) 1205LU cells transfected with NM23-H1 expression vectors maintain elevated 
protein levels relative to the parent cell as determined by western blot.  (B) Cells 
were grown under normal conditions and proliferation was assessed using MTS 
reagent. Data showed no significant difference in growth rate among stable 
transfectants and control cells.  
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Figure 2.5 NM23-H1 Mediated Inhibition of Motility and Invasion in 1205LU 
Cells Acts Independently of Its Three Known Enzymatic Functions.  
Evaluation of the (A) motility and (B) invasive capacities of the 1205LU panel of 
cell lines in response to FBS using Boyden chambers.  Asterisks indicate 
statistical significance (p < 0.05) among treatments based on their respective 
mean values as determined by one-way ANOVA (p < 0.001) and the Holm-Sidak 
method for all pairwise comparisons.  
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cancer.  Therefore, these results contradict the notion that histidine kinase 
activity mediates H1-dependent motility suppression, possibly representing an 
undiscovered mechanism in melanoma by which H1 reduces the locomotor 
activity of cancer cells.  If indeed the enzymatic functions of H1 are not needed 
for motility suppression in this setting as this data would suggest, it strongly 
implicates an alternate explanation such as kinase-independent physical 
interactions with other proteins and/or transcriptional regulation of motility-
associated genes as the means for achieving the observed phenotype. 
 
Conclusions 
The results presented here show for the first time the complete 
characterization of a number of non-functional mutants of recombinant NM23-H1.  
The identification of this panel of mutant variants has provided a means of 
classifying each in terms of their impact on kinase or nuclease functions, 
furthering our understanding of the biology of the H1 molecule.  While our results 
would predict that each amino acid residue targeted for substitution is the source 
of the associated enzymatic activity, the reports concerning instability of P96S 
cannot be ignored (79, 80, 102).  As a result, it is possible that our methods were 
not sensitive enough to observe a difference in protein structure, leading to an 
erroneous conclusion concerning P96S, which could lead to impairment of H1 
function strictly due to anomalies in secondary structure.  However, the studies 
referenced tested stability of the molecules following treatment with denaturants 
before examining oligomerization.  This could explain the failure to observe any 
differences in P96S structure here as experiments were conducted so as to 
maintain recombinant H1 in its proper orientation.  
While the structure-function analysis was extremely informative, perhaps 
the most important finding from this study came with the comparison of the 
motility suppression data to results from in vivo experimental and spontaneous 
metastasis assays conducted in nude mice with the same panel of transfectant 
cells. Carried out in the lab by colleagues Marian Novak and Qingbei Zhang, the 
analysis of the metastatic potential of these cells showed the enzymatic activities 
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of H1 to be necessary for blocking spontaneous metastasis, with exonuclease-
deficient mutant cell lines (E5A & K12Q) showing complete loss of suppression 
and the H118F mutant having an intermediate phenotype (32).  This is in stark 
contrast to the full motility suppression observed in 1205LU cells for all mutants 
tested when compared to the wild-type molecule.  The lack of correlation 
between migration and metastasis suppression suggests that in vitro motility and 
invasion assays are not the best indicators of metastatic potential, as H1-
dependent motility suppression almost certainly contributes to its metastasis 
suppressor function.  Additional underappreciated roles for H1 within the cell 
influencing metastatic potential, such as maintenance of genomic stability via 3’-
5’ exonuclease activity, may still exist.  More investigation is needed to better 
understand what contribution H1-dependent motility suppression has on 
metastasis as it is commonly accepted that impeding cell migration is likely the 
sole mechanism for generating the observed phenotype.  In this particular 
1205LU model system, however, metastasis suppression lacks clear correlation 
with in vitro motility and invasion assays, emphasizing the inadequacy of such in 
vitro systems when comprehensively studying the metastatic process. 
 
 
 
 
 
 
 
 
 
Copyright ©Joseph Robert McCorkle 2010 
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CHAPTER THREE 
 
Identification of Novel Genes Mediating NM23-H1 Dependent Motility 
Suppression in WM793 Melanoma Cells 
 
Introduction 
Our recent report concerning the effects of increasing H1 expression in 
the melanoma cell line 1205LU has shed new light on the necessity of the 
individual functions of H1 in mediating metastasis suppression (32).  Specifically, 
this study showed that H1 was unable to block lung colonization when 
transfectant cell lines overexpressing the NM23 isoform were introduced directly 
into the tail-vein of nude mice.  Observations in the lab did show however that H1 
was able to suppress metastatic spread in nude mouse models of spontaneous 
metastasis.  Spontaneous metastasis assays require the formation of a primary 
tumor and intravasation instead of direct introduction into the circulation, 
encapsulating even more of the metastatic process and as such, are a more 
accurate model for studying the multiple steps necessary for malignant spread.  
These results would suggest that H1 is acting on cells within the primary tumor, 
preventing the outgrowth and dissemination of a population of malignant cells.  
This makes sense in the context of the 1205LU in vitro motility and invasion 
studies as metastatic cells would need some motile capacity to metastasize. 
Thus, high levels of H1 expression would obviously put these cells at a serious 
disadvantage for successful spread.  The problem is that the data showed a lack 
of correlation between the in vitro and in vivo studies suggesting that H1-
dependent suppression of motility and invasion was not sufficient for blocking 
metastasis. So if there is more to the story than just blocking cellular invasion 
and motility, what else is H1 doing to prevent metastasis? Numerous possibilities 
exist however analyzing every one directly would not be feasible.  Knowing that 
most physiological processes will impact or are controlled by gene expression 
programs, the most comprehensive and logical approach to such a broad 
question is a high-throughput screen such as a gene expression microarray.  
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This rationale led to the development of a gene chip analysis assessing the 
impact of elevating otherwise low nm23-H1 expression levels in cells derived 
from a vertical-growth phase (VGP) human melanoma, in hopes of gaining 
insight into the types of processes H1 uses to mediate metastasis suppression. 
The cell line that was chosen for the differential expression analysis was 
WM793, a VGP melanoma cell type from which the 1205LU cells were derived 
(103).  These cells are tumorigenic and have exhibited the ability to colonize the 
lungs of nude mice following tail-vein injection, a process that was blocked by H1 
overexpression (personal communication, M. Novak).  Melanoma cells derived 
from the vertical growth phase are thought to possess the capability to 
metastasize and have a high degree of similarity to cells of corresponding distant 
metastases (93).  Furthermore, with 1205LU cells being established directly from 
WM793 cells and nearly identical patterns of DNA fingerprinting being reported 
(104), it was thought that many of the genes altered by H1-overexpression in 
these VGP cells were likely to be impacted in a similar manner in the metastatic 
derivative cell lines.  Therefore, the aim of this particular set of experiments was 
to identify genes differentially expressed between the WM793 control cells and 
H1-transfectants, then, look for common H1-dependent expression patterns that 
are present in the 1205LU panel which may be influencing metastatic potency.   
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Materials and Methods 
Cell lines and culture:  Vertical-growth phase (VGP) WM793 and metastatic 
WM1158 melanoma cell lines were a generous gift of Dr. M. Herlyn (Wistar 
Institute, Philadelphia, PA).  WRO82 thyroid adenocarcinoma cells were kindly 
provided by the late Dr. Stephen G. Zimmer (U. of Kentucky, Lexington, KY).  
The melanoma cell lines were maintained at 5% CO2, 37
o C in TU 2% growth 
medium composed of MCDB153: Leibovitz-15 (4:1; v:v) (Sigma, St. Louis, MO: 
Gibco, Carlsbad, CA) with 2 mM CaCl2 (Fisher Scientific, Pittsburgh, PA), 5 
g/mL insulin (Sigma, St. Louis) and 2% fetal bovine serum (FBS) (Gibco).  
WRO82 cells were grown at 10% CO2, 37
o C in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% FBS, 1 mM non-essential amino acids 
(Lonza, Allendale, NJ), 1 mM L-glutamine (Gibco), 100 units/mL penicillin and 
100 g/mL streptomycin (Lonza).  Stable transfection of the WM793 cells was 
achieved in the same manner and using the same constructs as described for 
1205LU cells in the previous chapter.   
 
Wound Healing Assays:  “Scratch” assays were conducted in 6-well tissue 
culture plates.  3x105 WM793 cells were seeded per well and allowed to attach 
for ~16 hours under normal growth conditions.  The next morning, TU 2% growth 
medium was changed to protein-free culture medium and the cells were “starved” 
for 4 hours.  A scratch was then generated in the monolayer of cells with a 200 
L pipette tip and 2 washes with media were used to remove any loosely 
attached cells.  The cells were then grown for 48 hours, in the absence of 
exogenous growth factors to reduce proliferation, at 37o C, 5% CO2.  For 
analyses, multiple images were captured (~4 per well) from the same areas of 
the scratch in 24 hour intervals using light microscopy (4X) and a Nuance 
imaging system (CRi, Woburn, MA).  Motile cells were counted and measured 
using ImageJ software (U.S. National Institute of Health, Bethesda, MD) (105). 
 
RNA isolation:  WM793 cells were initially seeded 1.5 x 105 in 100 mm culture 
dishes and grown for 3 days in TU 2% melanoma media to a confluence of 
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~80%.  Five replicate dishes of each mixed population of stable transfectants or 
parent cell lines were included and kept as separate and individual samples.  
Total cellular RNA was harvested using RNEasy RNA Extraction Kit (Qiagen) 
according to the supplied protocol.  Purified RNA samples were diluted to ~ 1 
mg/mL with RNAse-free deionized water and transferred to the University of 
Kentucky Microarray Core facility for cDNA synthesis, hybridization and 
scanning, using equipment and procedures described here: 
(http://www.mc.uky.edu/ukmicroarray/affymetrix.htm).   
 
Data analysis:  Raw intensity values were imported into Partek Genomics Suite 
for normalization and analysis.  Signals were subjected to background correction 
based on G-C content, sketch normalization (50000 points) and log2 
transformation.  Resulting intensities below 2 were removed as background noise 
and median values were assembled for collections of probes assigned to each 
gene to generate signal estimates (RMA method) corresponding to each 
treatment group.  Factors used for the multi-factorial analysis of variance 
employed by the software were both experimental (cell lines) and batch grouping 
(scan date).  Statistical analysis was performed across the entire experiment for 
overall ANOVA and pairwise comparisons were conducted between control cells 
and H1-transductants as well as between H1wt and mutant variants.  The same 
parameters were used for both gene-level and exon-level analyses, however 
different workflows provided by the software were necessary for separation of the 
two data sets.    
 
Validation of expression changes with semi-quantitative polymerase chain 
reaction:  Isolated RNA (1 g) was converted to cDNA using MultiScribe reverse 
transcriptase and random hexamer primers in 50 l reactions (Applied 
Biosystems, Foster City, CA).  Semi-quantitative polymerase chain reaction 
(PCR) was performed with TaqMan Universal PCR MasterMix without UNG and 
pre-designed TaqMan Gene Expression Assays (Applied Biosystems) using 100-
200 ng of cDNA.  The NM23-H1 gene was assessed with primers (5’-3’; forward- 
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CAGAGAAGGAGATCGGCTTGT; reverse-GCACAGCTCGTGTAATCTACCA) 
and a FAM dye fluorescent probe (TTCCTCAGGGTGAAACC).  A list of 
additional primers pre-designed and commercially available (Applied Biosystems) 
are described in Table 3.1.  Signals were quantified from FAM reporter dyes 
found on an MGB probe incorporated with a given primer set, and detected with 
an ABI Prism 7700 (Applied Biosystems).  Target gene expression levels were 
normalized to endogenous beta-2-microglobulin mRNA (Human B2M 
Endogenous Control, Applied Biosystems). 
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Table 3.1 Primers Used for Semi-quantitative Polymerase Chain Reaction 
(PCR) Validation of Microarray Results 
Gene# 
(Assay ID*) RefSeq 
Exon 
junction 
Length of 
amplicon (bp) 
EREG 
(Hs00154995_m1) NM_001432.2 1-2 118 
MMP3 
(Hs00968305_m1) NM_002422.3 6-7 126 
NETO2 
(Hs00983152_m1) NM_018092.3 7-8 66 
MAGEA1 
(Hs00607097_m1) NM_004988.4 1-2 124 
LRP1B-5’ 
(Hs01069129_m1) NM_018557.2 3-4 125 
LRP1B-3’ 
(Hs00218582_m1) NM_018557.2 89-90 91 
# Official gene symbol according to HUGO Gene Nomenclature Committee 
* Product number for pre-designed primer sets specific for a given gene available 
from Applied Biosystems: 
(https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=ABGEKeywo
rdSearch&catID=601267).  All probes are labeled with FAM fluorescent dye. 
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Results 
H1 Overexpression Leads to Reductions in WM793 Cell Motility 
Empty-vector, wild-type and mutant (E5A, K12Q, H118F, and P96S) NM23 
constructs were introduced by stable transfection into WM793, VGP melanoma 
cells. Although these cells are evolutionarily similar to 1205LU cells, motility and 
invasion studies conducted in the same manner as before in Boyden chamber 
systems failed to show any reduction in cell migration of WM793 cells when 
overexpressing wild-type or mutant H1.  This was unexpected as these cells 
were predicted to behave like the 1205LU cells and exhibit H1-dependent 
reductions in motility.  In order to eliminate the possibility that this was the result 
of technical limitations of the assay, an alternate method was used to verify that 
no phenotypic variation existed.     
 Wound healing, or “scratch”, assays are an extremely simple method 
commonly used in cell culture systems to assess the ability of a monolayer of 
cells to repopulate a freshly denuded area in a culture dish.  Although these 
assays limit the ability to stimulate a cell’s directional chemotaxis with exogenous 
attractants, they can be very informative when looking at random motility within a 
population of cells.  In this study, there was no H1-dependent difference in the 
collective movement of the monolayer of cells as determined by closure of the 
“wound” over time (Figure 3.1).  However, a few striking differences were 
observed between the control cell lines and the NM23 transfectants.  First, the 
total number of individual cells which were breaking away from the monolayer 
and migrating into the center of the scratch was significantly higher in the control 
cells than the H1-overexpressing melanoma cells (Figure 3.2(A)).  In addition, the 
majority of these relatively motile control cells that would gather in the wounded 
area had stark differences in morphology, acquiring a neuronal-like shape and 
extending a pair of extremely long, thin dendrites in opposite directions from the 
cell body (Figure 3.2(C)).  This was quantified using imaging software and is 
presented as average cell length of the motile cells within the “scratch” at 48 
hours (Figure 3.2(B)).   Mean cell lengths of migrating cells showed a significant 
difference from controls, yet no variation among any of the H1-transfectants. 
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Figure 3.1 WM793 Transfectants Show No Differences in Rates of Wound 
Closure.  Confluent cell monolayers were scratched with a 200 L pipette tip and 
cultured for 48 hours in protein-free growth media.  Images were acquired at 4X 
magnification every 24 hours, including at initiation of the experiment for 
reference.  Area of denuded space between opposite monolayer fronts was 
quantified from these images using ImageJ software (NIH) and compared to one 
another to determine the proportion of the wound that was closed.  Statistical 
analysis using the Kruskal-Wallis one-way ANOVA on ranks showed no 
statistical significance per time point.   
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Figure 3.2 Forced Expression of H1 Reduces Single Cell Motility and 
Prevents a Correlated Morphological Change in WM793 Cells. WM793 cells 
were seeded at confluence and allowed to attach for ~18 hours before serum-
starving the cells for 4 hours.  Cells were then removed along a “scratch” and 
closure of the denuded area was monitored for 48 hours.  The motility (A) and 
length (B) of single cells within the scratched area at 48 hours were determined 
from images captured at 4X magnification and quantified using ImageJ analysis 
software. (* = Statistical significance according to 1-way ANOVA and Holm-Sidak 
method of pairwise comparisons (p < .05) for single cell motility (A). Kruskal-
Wallis 1-way ANOVA on ranks and Dunn’s method were used for comparisons of 
cell length in (B)). (C) Typical cellular morphology seen among motile cells from 
the control and H1 lines under light microscopy (4X). 
C. 
WM793 
WM793-pCI 
WM793-H1-wt 
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While the H1-dependent reduction in cell motility for these populations of cells is 
modest when compared to what was seen in the 1205LU model, the correlation 
between the observed morphological change and migratory ability strongly 
suggests some type of physiological relevance, although this connection is not 
understood at this point.  These data do provide evidence that H1 is able to 
suppress random migration, albeit in what appears to be a fairly small 
subpopulation of the non-metastatic WM793 melanoma cells, a novel finding in 
this particular cell line.   
In accordance with the results in 1205LU cells, mutations disrupting the 
kinase activities alone (H118F and P96S) had no bearing on motility suppression 
conferred to the WM793 cells showing agreement between the two studies 
despite utilization of different techniques.  Two other mutant lines, E5A and K12Q, 
showed a similar trend to wild-type H1 in total number of motile cells yet failed to 
reach statistical significance.   
 
Identification of Genes Regulated by H1 Using Microarray Analysis  
In an effort to determine mediators of H1-dependent suppression of cell 
migration, differential gene expression analysis was conducted on the WM793 
stable transfectants and control cells.  Prior to the current study, microarray 
analysis had been conducted to examine the effects of H1-overexpression in two 
aggressive cell lines lacking endogenous H1 expression, a metastatic melanoma 
cell line WM1158, and WRO82, cells derived from a metastatic human thyroid 
carcinoma.  In these two lines, H1 levels were elevated through the use of 
adenoviral delivery and RNA was collected 48 hours later and hybridized to U133 
human genome arrays (Affymetrix).  A lacz containing adenovirus was included 
as a control for the infection itself.  Once the data was analyzed, it became 
apparent that the transduction of these cells itself was resulting in global gene 
expression changes which complicated downstream analysis by increasing the 
likelihood of false positives and masking true effects of H1-WT on the 
transcriptome.  Therefore, microarray analysis using the WM793 panel of stable 
transfectants was initiated in order to clarify results from the previous studies 
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while also providing a means of investigating the effect of specific H1 mutations 
on the expression profiles.   
A recent report implicating NM23 in splicing of nascent mRNA (106) led to 
the decision to use an alternate gene-chip platform to study the WM793 panel. 
The human Exon 1.0 ST array (Affymetrix) was chosen allowing for the detection 
of multiple levels of genetic variation by examining the entire transcript. This type 
of analysis measures changes in both abundance (gene-level) and alternative 
splicing (exon-level) of gene transcripts.  Following data normalization and 
statistical comparisons, 143 gene-level and/or alternatively spliced targets were 
found to be significantly different following overexpression of H1 in WM793 cells.  
This list of genes was used for grouping based on functional ontology; however, 
the lack of thorough characterization of the vast majority of splice variants in the 
human genome makes down-stream consequences and validation of a great 
number of these species extremely difficult.  Therefore, most of the genes that 
were chosen for further investigation were based on the gene-level lists only.   
Realizing that inherent differences between the chip platforms chosen would 
confound variations, the previously generated expression data was reanalyzed 
with the same methods used for the exon array.  Raw signal intensity files were 
normalized and compared statistically using Partek® Genomics Suite (GS) 
software.  Partek employs a mixed model analysis of variance and uses the 
method of moments estimation (107) as a means of estimating variation 
attributed to random effects.  Initially, the resultant profiles of differentially 
expressed genes for WM793 control cells were compared to stable transfectant 
cell lines forced to express NM23-H1 wild-type or mutant variants.  A final list of 
differentially expressed, H1-wt regulated genes was created using criteria 
consisting of p-values ≤ 0.01 and relative fold changes of at least 1.5 in either 
direction.  This subsequent gene profile consists of 126 genes with 107 being 
upregulated and 19 downregulated.  While there were an unexpectedly low 
number of genes showing fold-changes of two or more, pushing the detection 
limits of most routine quantitative techniques used to assess transcript levels, 
confirmation of results by RT-PCR was still conducted on select targets with 
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greater relative differences in expression and relevance to cancer and/or NM23-
H1 (Table 3.2).  These include the ErbB receptors ligand epiregulin (EREG), 
melanoma antigen A1 (MAGEA1), matrix metalloproteinase 3 (MMP3) and 
NETO2.  Forced expression of H1 was confirmed as well with stable transcript 
levels being 10-15-fold higher than in the control cells.   
Examination of the exon-level data identified one gene in particular that 
displayed extremely significant differences in alternative-splicing patterns in 
response to H1-wt overexpression.  LRP1B, a member of the low-density 
lipoprotein receptor family, was represented by at least two species of transcripts 
in the analysis, with one full-length and one truncated message consisting of just 
the first fourteen exons of the intact gene product detected.  From visualization of 
the splicing patterns using Partek GS, it would appear that in the WM793 control 
cells this short form of the transcript is expressed, identified by ENSEMBL as a 
novel protein coding transcript (ENST00000434794).  Overexpression of H1 
induced a shift from the spliced to the full length mRNA including all 91 exons, 
however, it did not appear to stimulate increased transcription.  Regions 
interrogated at the 5’ end (spanning exons 3 and 4) of the message using RT-
PCR showed no expression differences between H1 and control cells whereas 
targeting areas corresponding to exons 89 and 90 at the 3’ end showed a mean 
H1-dependent increase of almost 16-fold.  Although the biological meaning of the 
different splice variants is unknown, it should be noted that this gene is a putative 
tumor suppressor.  Expression aberrancies and loss have been noticed in a 
number of cases of non-small cell lung cancers (NSCLC), earning the nickname, 
LRP-deleted in tumors (LRP-DIT) (108).  It is possible that the absence of 
transcripts in NSCLC is due to failure to detect this shortened transcript, raising 
the possibility that the truncated form of this transcript may be tumorigenic, while 
the full-length message is found in normal cells. 
RT-PCR analysis of these same genes in the 1205LU panel showed no 
expression differences among the lines tested, with two targets dropping below 
the detection limits (Table 3.3).  Failure to see correlation between the profiles for 
the two transfected cell panels, at least for these genes, suggested that the  
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Table 3.2 Validation of Genes Identified with Expression Analysis Using RT-
PCR#  
Target 
genes 
WM793 Cell Lines 
 -H1wt -E5A -K12Q -P96S -H118F 
NM23-H1 9.4 +/- 0.8 11.8 +/- 1.1 11.0 +/- 0.8 11.5 +/- 0.2 15.5 +/- 0.4 
LRP1B  
(exon 3-4) 
1.1 1.1 2.0 1.3 1.2 
  (89-90) 15.7 +/- 3.2 2.0 +/- 0.6 1.7 +/- 0.4 1.4 +/- 0.3 1.2 +/- 0.4 
EREG 2.6 +/- 0.2 5.8 +/- 0.05 2.2 +/- 0.3 3.2 +/- 0.04 1.4 +/- 0.2 
NETO2 2.9 +/- 0.2 7.7 +/- 2.0 1.2 +/- 0.3 1.2 +/- 0.02 1.3 +/- 0.1 
MAGEA1 4.7 +/- 0.3 2.9 +/- 0.6 1.5 +/- 0.1 1.8 +/- 0.2 2.4 +/- 0.2 
MMP3 1.5 +/- 0.2 2.2 +/- 0.5 2.0 +/- 0.4 1.3 +/- 0.02 1.5 +/- 0.1 
  
Up-regulated genes; Down-regulated.  #Genes examined are listed vertically 
with individual cell lines listed across the top.  Numbers represent relative 
differences when compared to the WM793 parent cell line with semi-quantitative 
RT-PCR.  According to the analysis, the LRP1B gene was found to be 
alternatively spliced in the H1-wt cell line. Two different regions of the same 
transcript (listed in parentheses) were interrogated to verify this result.  The 
boundary between exons 3 and 4 were compared to that of exons 89-90. 
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Table 3.3 Genes Differentially Expressed in WM793 Cells are Unaltered in 
1205LU Cells Following H1-Overexpression 
Cell Line Target Genes 
  EREG NETO2 MAGEA1 
LRP1B 
(exon 3-4) 
LRP1B 
(exon 89-90) 
WM793 
(Parent) 
1 1 1 1 1 
NM23-
H1wt 
2.6 2.9 4.7 1.1 15.7 
-E5A 5.8 7.7 2.9 1.1 2.0 
-K12Q 2.2 1.2 1.5 2.0 1.7 
-P96S 3.2 1.2 1.8 1.3 1.4 
-H118F 1.4 1.3 2.4 1.2 1.2 
      
1205LU 
(Parent) 
No 
amplification  
(NA) 
1 NA 1 1 
NM23-
H1wt 
NA 1.5 NA 1.0 1.0 
-E5A NA 1.1 NA 1.1 1.2 
-K12Q NA 1.1 NA 1.5 1.6 
-P96S NA 1.1 NA 1.1 1.4 
-H118F NA 1.0 NA 1.6 1.6 
 
Up-regulated; Down-regulated relative to parent cell line as determined with 
semi- quantitative RT-PCR. 
 
 
 
 
 
 
52 
 
ability to translate the findings interchangeably between lines may not be as easy 
as originally anticipated.  It is possible that the metastatic derivative cells have 
undergone significant changes making them fundamentally different from WM793 
cells.  Alternatively, it could simply be that the genes interrogated here are not 
the key factors mediating the H1 phenotype and other members of the 
expression profile, not yet validated in 1205LU, are essential for suppression. 
To better understand the greater biological meaning of the gene 
expression profiles for the cell lines, grouping based on ontology using the 
DAVID database (NCBI) was performed on the 143 genes showing H1-
dependent differences.  A selection of genes of interest are grouped by cellular 
function and presented here (Table 3.4).  From the classifications, the processes 
that were deemed to be significantly enriched according to the statistical analysis 
using DAVID (p < .05) were translation and cell growth.  Other groupings listed 
are for classification purposes and do not represent biological enrichment per se.      
The gene lists from the two metastatic lines proved to be much larger, 
again, more than likely due to off-target effects of the adenoviral infection.  
Analysis of the WM1158 transcriptome revealed 1849 genes were regulated by 
H1 while 1003 genes were differentially expressed in the WRO82 cell line.  
These lists were created by filtering the data to include only genes showing 
statistical significance (p < .01) between the H1 transductants and the two 
controls (uninfected & lacz infected).  The subsequent expression profiles were 
then used to create lists of functionally associated genes enriched by H1 
overexpression in the metastatic cell lines, WRO82 and WM1158, as determined 
by Ingenuity Pathway Analysis (IPA).  A selection of significant genes identified 
within each ontology group is presented (Table 3.5 [WM1158]; Table 3.6 
[WRO82]). 
 
Genes Tracking with the Motility Suppression Profile Modulate Cell 
Signaling 
To more specifically investigate how H1 is inhibiting motility in these cell 
lines, the microarray data was filtered in a manner that fit the observed  
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Table 3.4 Grouping Based on Associated Biological Process of NM23-H1-
Dependent Genes Differentially Expressed in WM793 Cells1 
  
Induced 
by H13  
Repressed 
by H1 
Alternatively-
spliced 
Translation/ MRPL16      
RNA processing (9.1%)2 MRPS6      
  MRPS11      
  PTRH1      
  RPL6      
  RPL17      
  RPL35      
  RPS27L      
   EXOSC8     
  PRPF18      
  RBM17      
  TRMT5      
  ZCRB1      
        
Cell Death (7.0%) BCL2A1   SYNE1   
  BNIP3      
  ALDOC*      
  ATXN3      
  CASP1      
  CASP4      
  DYNLL1      
  SRGN      
  SIAH1      
        
Cell Movement/ CD9  SEMA3B MET   
Adhesion (7.7%) SCG2  FREM2 NRCAM   
  SIAH1  LGALS3BP SLIT3  
    SIRPA    
    SDC3    
        
Cell-cell Signaling 
(5.6%) PARK7  APOE AMH   
  ATXN3  SEMA3B    
  CXCL11      
  EREG*      
  GDF15      
        
Cell Cycle/ N6AMT1* APOE NRCAM   
Growth/  ESM1*   LZTS1   
Proliferation (11.9%) IGFBP3   MET    
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Table 3.4 (Continued) 
 
Cell Cycle/     IGFBP4*      
Growth/  MPHOSPH8     
Proliferation (11.9%)  NDC80*      
  OIP5      
  RAD51      
  CDT1      
  EREG*      
  SIAH1      
  EMP1      
  ZNF259      
1Biological annotation assigned from DAVID Bioinformatics Resources 6.7 
(http://david.abcc.ncifcrf.gov/). 2Percentages represent proportion of total H1-
regulated genes assigned to each biological process. 3Genes are listed by their 
official gene symbol as denoted by HUGO Gene Nomenclature Committee. 
*Genes which are found to be alternatively-spliced as well as induced 
transcriptionally by H1.   
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Table 3.5 Genes Altered by H1-wt Overexpression in WM1158 Cells 
  Induced by H1-wt  Repressed by H1-wt  
    Gene*  p-value    Gene      p-value 
Cell Death 
 
 
GADD45A 9.19E-06  TRIM2 7.81E-05  
 DUSP5 1.11E-05  CASP6 0.000259  
 AKAP12 4.66E-05  ANP32A 0.000396  
 PPIF 0.000209  MBD4 0.000867  
 NPTX1 0.000212  TRIB2 0.000884  
 KLF6 0.000252     
 G0S2 0.001297     
        
Cellular 
Growth/ 
Proliferation 
 GEM 6.16E-07  PADI4 7.35E-07  
 DUSP1 1.88E-06  CALM1 3.62E-05  
 EGR1 6.91E-05  EDF1 0.000229  
 ATF3 0.000211  CAPRIN1 0.000994  
 PPP1R15A 0.000262  PCNA 0.001054  
 MAP2K7 0.000366  TOB1 0.001106  
 MAFF 0.000381  CCNG2 0.001508  
 SGK1 0.001155  ETFDH 0.003576  
 RBM9 0.002231     
        
Cellular 
Movement 
 STC1 4.82E-07  CD24 8.59E-06  
 MMP3 1.35E-05  TPM1 7.33E-05  
 HSP90AA1 1.38E-05  CAPZB 0.000191  
 MMP1 1.72E-05  THBS1 0.002831  
 AJAP1 6.80E-05  CAPZA2 0.002978  
 ITGB3 7.19E-05     
 NT5E 0.000111     
 SERPINB2 0.000206     
 CD55 0.000244     
 TFPI2 0.001135     
        
Cell 
Signaling 
 IL8 9.20E-06  NAT1 0.000901  
 IL11 3.30E-06  SS18 0.00378  
 EIF5 7.58E-05     
 IL1A 0.00015     
 CALR 0.000602     
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Table 3.5 
(Continued) 
Development 
   ANGPT2 4.65E-08  RAB4A 3.81E-05  
    PTHLH 9.02E-06  TTC3 0.000209  
 MYC 1.32E-05  SRI 0.000279  
 AREG 2.56E-05  ADH5 0.000312  
 HBEGF 6.19E-05  BMP4 0.000536  
 IFRD1 6.41E-05  BBS4 0.001483  
 JUN 0.000142  DLG1 0.001534  
 NID1 0.000213  NUP133 0.001879  
 TFPI 0.000551  VEZF1 0.006567  
 FGF5 0.000605     
 SYNE1 0.001985     
 INHBA 0.002474     
*Genes are listed by their official gene symbol as denoted by HUGO Gene 
Nomenclature Committee. 
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Table 3.6 Genes Altered By H1-wt Overexpression in WRO82 Cells 
  Induced by H1-wt  Repressed by H1-wt  
  Gene* p-value  Gene p-value  
Cellular 
Movement 
 CSF2RB 3.84E-07  ZYX 0.000498  
 ADAM21 6.68E-05     
 TIMP4 0.00026     
 CD3E 0.000288     
 COL4A3 0.000505     
 F9 0.000806     
 SEMA6D 0.001344     
 LGALS8 0.001191     
 ELMO1 0.002452     
        
Cellular 
Growth/ 
Proliferation 
 SSX1 5.46E-05  GATA3 0.000462  
 ESR1 6.78E-05  FIP1L1 0.000929  
 CYP2C9 0.000142  PRC1 0.000995  
 RASGRF1 0.000365  UTP6 0.00134  
 STAT5A 0.000583  CDK7 0.001453  
 ST6GAL1 0.000615  STAT1 0.002397  
 GNAO1 0.001036  NUP98 0.002837  
    ZFP36L2 0.004026  
    SERTAD2 0.004269  
    CCNA2 0.004279  
        
Cell Death 
 SERPINB9 1.10E-05  RPS3 5.10E-05  
 RAD51L3 1.48E-05  ATP5S 7.79E-05  
 KIF5A 0.000191  CCT6A 0.000199  
 SERPINB4 0.000711  PQBP1 0.000323  
 PRDM2 0.000817  PSMB1 0.001074  
 SFRP1 0.00096  ABCE1 0.00134  
 PAK6 0.001913  ASNS 0.001577  
    CDC42EP3 0.001804  
    ITGB3BP 0.001859  
    BCL2L1 0.002547  
    PDCD5 0.002846  
    HSPA4 0.003247  
    PRDX6 0.00393  
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Table 3.6 
(Continued) 
Development 
 
 
NFKB2 1.61E-05  MAEA 0.000559  
 ELAVL2 0.000133  FAS 0.00059  
 TYRP1 0.000154  GRSF1 0.000731  
 SRPX2 0.000254  IRF7 0.001005  
 SHROOM2 0.000482  XBP1 0.003044  
 UTS2 0.000645  EDF1 0.003306  
 EFNB3 0.001143     
 TRIB2 0.001148     
 REL 0.001845     
 ID2 0.004968     
        
Cell 
Signaling 
 MS4A1 3.26E-05  PPID 9.95E-05  
 HGF 3.86E-05  CAP1 0.002622  
 PDE3B 6.44E-05     
 HRH3 9.50E-05     
 CX3CR1 0.000118     
 CXCL10 0.000121     
 CCR1 0.000222     
 TGFA 0.000374     
 IL4 0.000596     
*Genes are listed by their official gene symbol as denoted by HUGO Gene 
Nomenclature Committee. 
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phenotype.  In other words, the genes that were shown to be differentially 
expressed in the H1-wt cell line were further enriched for coordinately regulated 
genes in the P96S and H118F mutant transfectants, thus tracking with the motility 
data.  The criteria for enrichment did not consider the E5A- and K12Q-regulated 
genes as these cells did not quite reach statistical significance in the scratch 
assays, showing an intermediate phenotype not different from either control or 
wild-type transfectants.  The final gene list containing 59 genes facilitated the 
downstream investigation necessary for characterizing any proposed mechanism 
of action by pinpointing the genes most likely to be mediating the H1-dependent 
effects on migration (Table 3.7).  Further enrichment was achieved by sorting the 
gene lists from all three studies into a Venn diagram in order to look for regions 
of similarity and showing that only nine genes are coordinately altered by H1-wt 
in these lines (Figure 3.3).  These include seven up-regulated (BRAP, DIDO1, 
EXOSC8, NLGN4X, PABPC3, POP5, SRPX2) and two down-regulated genes 
(LRP3 and SEMA4F).  The only gene from this list that also fit the motility profile 
was BRAP, an ubiquitin ligase molecule required for proper conduction of MAPK 
signaling through Raf and MEK, suggesting yet another important role for H1 in 
this pathway. 
 
Conclusions 
Although still statistically significant, the relative reduction to motility in 
response to H1 overexpression in the WM793 cell line is unexpectedly small, 
which is quite interesting considering that these cells have lower metastatic 
potential but are no less tumorigenic than the 1205LU cells.  As classically 
defined metastasis suppressors mediate their effects exclusively on cells which 
are metastatically competent, one might expect a more modest impact on a cell 
derived from a VGP cell line.  Therefore, it is possible a quantitative difference 
may only be observed in the most aggressive cells within a population of VGP 
melanoma cells.  Consequently, many WM793 cells may be unaffected by H1 
overexpression simply due to the stage of progression or level of  
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Table 3.7 List of Genes Regulated by H1 Which Fit the Motility Profile 
Observed in the WM793 Panel of Transfectants
Induced by H1-overexpression  Repressed by H1-overexpression 
Gene Name* 
Gene 
Symbol   Gene Name 
Gene 
Symbol 
major 
histocompatibility 
complex, class II, DP 
beta 1 
HLA-DPB1  
steroid-5-alpha-
reductase, alpha 
polypeptide 1 
SRD5A1 
growth differentiation 
factor 15 
GDF15  
carnitine O-
octanoyltransferase 
CROT 
zinc finger protein 195 ZNF195  
Sad1 and UNC84 
domain containing 2 
SUN2 
WD repeat domain 54 WDR54  SUMO1 pseudogene 3 SUMO1P3 
ribosomal protein S27-
like 
RPS27L  
Rho guanine nucleotide 
exchange factor (GEF) 
19 
ARHGEF19 
LYR motif containing 5 LYRM5  
solute carrier family 22 
(organic cation/carnitine 
transporter), member 5 
SLC22A5 
APBB1-interacting 
protein 1 
APBB1IP  zygote arrest 1 ZAR1 
peptidyl-tRNA 
hydrolase 1 homolog 
PTRH1  retbindin RTBDN 
BCL2/adenovirus E1B 
19kDa interacting 
protein 3 
BNIP3  
IQ motif containing 
GTPase activating 
protein 2 
IQGAP2 
small nuclear RNA 
activating complex, 
polypeptide 3 
SNAPC3  cytochrome P450 4V2 CYP4V2 
NDC80 homolog, 
kinetochore complex 
component 
NDC80  
zinc finger, FYVE domain 
containing 28 
ZFYVE28 
RAD51 homolog RAD51  
mesenchyme homeobox 
1 
MEOX1 
kelch domain 
containing 2 
KLHDC2  
solute carrier family 6 
(neurotransmitter 
transporter, L-proline), 
member 7 
SLC6A7 
ankyrin repeat domain 
37 
ANKRD37  
probable tRNA (uracil-
O(2)-)-methyltransferase 
C4orf23 
minor 
histocompatibility 
antigen HA-8 
KIAA0020  
maltase-glucoamylase 
(alpha-glucosidase) 
MGAM 
M-phase 
phosphoprotein 8 
MPHOSPH8  
lymphocyte-activation 
gene 3 
LAG3 
RNA binding motif 
protein 17 
RBM17  
metallothionein 1J 
(pseudogene) 
MT1JP 
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Table 3.7 (Continued) 
lysosomal-associated 
membrane protein 1 
LAMP1  SEC14-like 5 SEC14L5 
NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 7 
NDUFA7    
neuritin 1 NRN1    
BRCA1 associated 
protein 
BRAP    
enolase 2 ENO2    
DNA replication factor 
Cdt1 
CDT1    
methyl-CpG binding 
domain protein 6 
MBD6    
zinc finger, MIZ-type 
containing 1 
ZMIZ1    
centromere protein C 
1 
CENPC1    
sushi-repeat-
containing protein, X-
linked 
SRPX    
very low density 
lipoprotein receptor 
VLDLR    
ZW10, kinetochore 
associated, homolog 
ZW10    
eukaryotic translation 
initiation factor 3, 
subunit M 
EIF3M    
TANK-binding kinase 
1 
TBK1    
non imprinted in 
Prader-Willi/Angelman 
syndrome 2 
NIPA2    
zinc finger protein 267 ZNF267    
Emerin EMD    
THAP domain 
containing 8 
THAP8    
TIMP 
metallopeptidase 
inhibitor 1 
TIMP1    
cytoskeleton 
associated protein 2 
CKAP2    
retinoblastoma binding 
protein 7 
RBBP7    
DnaJ (Hsp40) 
homolog, subfamily B, 
member 1 
DNAJB1    
ubiquitin-conjugating 
enzyme E2Z 
UBE2Z    
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Table 3.7 (Continued) 
phosphoseryl-tRNA 
kinase 
PSTK    
Genes are listed in descending order from highest to lowest relative fold-change 
(Parent vs. H1-wt; p ≤ 0.01).  Genes included also exhibited p ≤ 0.075 in H118F 
and P96S cell lines vs. parent cells with expression changes similar to H1-wt 
cells. 
Annotation from NetAffx (https://www.affymetrix.com) 
Official gene symbol according to HUGO Gene Nomenclature Committee 
BRAP is highlighted indicating the only gene in this list also induced in WM1158 
and WRO82 cells following H1 overexpression 
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Figure 3.3 Venn Diagram Showing Relative Numbers of H1-Dependent 
Genes in Each Cell Type.  Statistically significant genes (p ≤ .05) were identified 
with microarray analysis in the three cell lines shown (WM793, WM1158, 
WRO82) following H1-overexpression.  Numbers of genes in each group are 
indicated for each relationship. A total of nine genes were found to be altered in 
all three lines.  
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aggressiveness.  If as expected, only an extremely small proportion (≤ .01%) of 
cells shed from a primary tumor are able to successfully metastasize (109), the 
disseminated cells that thrive possess advantageous traits that allow for clonal 
expansion at the distant site, characteristics that the vast majority of cells found 
at the point of origin do not have.  This establishes a population of cells much 
more homogeneous than the highly heterogeneous cells in the primary tumor, 
which probably possess specific attributes acted upon by an MSG such as 
NM23-H1.  Therefore, an abundance of less aggressive cells present in VGP 
melanoma may explain why the overall reduction in motility is to a much smaller 
degree than what was observed in 1205LU cells.   
A technical difference in the two motility assays used could also contribute 
to the difference in results.  In the scratch assays, cells were seeded at 
confluence, inducing the formation of cell-cell contacts prior to generating the 
wound.  This negatively impacts the single cell motility through contact inhibition 
and forces the cells to disassemble intercellular junctions before migrating into 
the free space.  When WM793 cells were plated more sparsely, no differences in 
motility between H1-transfectants and control cells were observed using this 
assay (data not shown), suggesting that the role of H1 may be important for 
maintaining cell-cell adhesion, possibly ensuring tissue integrity. 
The morphological differences observed between the H1 panel and 
control cells in the WM793 line are extremely intriguing.  The thin, neurite-like 
projections extending bilaterally from the control cells seem exacerbated with 
time in protein-free media, but are positively correlated with enhanced motility as 
well.  And while many H1 transfectants do maintain a spindle-shaped phenotype, 
the presence of these long dendrites is lacking, with most H1-overexpressing 
motile cells retaining a shorter spindle or rounded epithelial morphology.  An 
attempt to explain this phenomenon at this point would be speculative however, 
similar observations in HT-1080 fibrosarcoma and MDA-MB-231 carcinoma cells, 
deemed a “mesenchymal to amoeboid transition”, correlated invasiveness with 
such a change in cell shape (110).  In these cells, highly elongated spindle 
morphologies also corresponded to enhanced cell motility and invasion whereas 
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rounded, “amoeboid” shape changes were associated with relative immobility.  
The enhanced movement in the referenced study was linked to increased 
pericellular proteolysis, alterations to Rho activity and changes to structural and 
adhesion molecules such as F-actin and 1-integrin. 
Interestingly, the ERK-MAPK pathway has also been associated with a 
similar transition in BE colon carcinoma cells (111).  As reported, signaling 
dynamics down-regulated Rho activity while enhancing Rac through ERK-
dependent Fra-1 expression, increasing motility through the generation of bipolar 
protrusions, as well as reductions to numbers of stress fibers and focal 
adhesions.  Investigating the impact of these pathways on migration in other 
systems is increasing and the link between a “mesenchymal” morphology and 
enhanced invasive potential has been strengthened as supporting evidence 
mounts (112).  With the Raf-ERK signaling axis being implicated in the H1-
dependent motility profile through the identification of BRAP, and a 
corresponding fibroblastoid morphology seen in the more migratory cells, the 
expression profile was revisited.  In addition to BRAP, IQGAP2 and LCN2 were 
also differentially expressed and have been linked to the MAPK cascade.  As a 
result, these genes were chosen for further investigation to assess their 
contribution to H1-mediated reduction in aggressiveness of melanoma cells.   
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CHAPTER FOUR 
 
NM23-H1-Dependent Expression Changes of the BRAP and IQGAP2 Genes 
Facilitate Motility Suppression 
 
Introduction 
 The discovery of metastasis suppressor genes and their subsequent 
characterization have identified commonality among associated cellular 
functions, most importantly a consistent impact on signal transduction pathways.  
While in many cases it is unclear exactly how modulation of these cascades is 
occurring, familiar components including MAP kinases, small GTPases Rho and 
Rac, and receptors linked to tyrosine kinase and G-protein coupled signaling 
have all been targeted by metastasis suppressors (113).  In the case of NM23, 
several lines of evidence exist suggesting that the H1 isoform is able to affect 
ERK-MAPK signaling through KSR phosphorylation (38), regulation of oncogenic 
Ras (114), Rad (51), and Rac1 (52).  ERK activity has been shown relevant to 
metastasis in studies of motility and invasion (115, 116), epithelial-mesenchymal 
transition (EMT) (117), lymphatic spread (118, 119) and in vivo models of 
metastatic disease (120, 121).  Examination of the H1-dependent gene 
expression data has bolstered interest in this pathway as it appears that H1 is 
controlling expression of several genes whose products are effectors or 
modulators of MAP kinase signaling.   
 BRCA1 associated protein (BRAP), also known as IMP for “impedes 
mitogenic signal propagation”, is induced by H1 in two melanoma cell lines, 
WM1158 and WM793.  Importantly, both of these cell lines harbor V600E 
activating mutations to B-Raf.  The gene product of BRAP is an E3 ubiquitin 
ligase and Ras effector protein that acts as a negative modulator of MEK and 
ERK activation through preventing the assembly of Raf-MEK complexes (122).  
Coincidentally, BRAP blocks signal transduction by inactivating KSR and 
disrupting its ability to link Raf with MEK, inhibiting downstream phosphorylation 
in the absence of mitogenic stimulation.  This effect is very similar to descriptions 
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of the interaction between H1 and KSR representing a novel, but possibly 
redundant mechanism by which NM23 is impeding MAP kinase signal 
transduction.  Furthermore, inhibition by BRAP is specific for negative regulation 
of the amplitude of ERK activation, with no impact on the timing or duration of the 
response, however, other common MAPK signaling molecules (e.g., JNK and 
Akt) are unaffected (122, 123).  This reduction in ERK activity is again likened to 
the effect of H1 overexpression described in MDA-MB-435 cells (113).  
 NM23 induced the expression of the lipocalin-2 (LCN2) gene in the 
WM793 cell line as well.  Although the expression of LCN2 increases following 
malignant transformation of epithelial cells from the breast, lung, colon and 
pancreas, suggesting an oncogenic function (124, 125), it also demonstrates the 
ability to restore expression of E-cadherin and cell polarization, characteristics of 
normal epithelium (126).  The gene product exerts unique effects on Ras-
transformed epithelial cells that have undergone EMT, a characteristic common 
among many metastatic cancer cells which is thought in many cases to drive 
metastatic progression.  LCN2 has exhibited the ability to reverse many 
characteristics of EMT in Ras-transformed cells, leading to inhibition of tumor 
growth and cancer metastasis (127).  Specifically, LCN2 overexpression was 
shown to promote E-cadherin stabilization which is opposed by activated MEK, 
through uncoupling signal transduction between Ras and Raf in 4T1 murine 
mammary carcinoma cells transfected with constitutively active H-ras.  Although 
the actions of LCN2 appear to act immediately upstream of Raf, demonstrated in 
the presence of oncogenic Ras, the impact on cells containing constitutively 
activate B-raf has not been described.  Therefore, the ability of LCN2 to reverse 
any negative effects of hyperactivated Raf signaling is unknown but induction of 
expression by H1 implicated this molecule as a potential player in NM23-
dependent modulation of MAP kinase responsiveness in certain contexts.  
 A third gene thought to influence mitogen-activated signaling identified by 
microarray analysis was IQGAP2.  Surprisingly, this gene is a putative tumor 
suppressor (128), although its expression was reduced in response to elevated 
H1 levels in WM793 cells and observations of IQGAP2 induction have been 
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noted in pancreatic and colorectal cancer studies (129, 130).  In addition, the 
oncogenic isoform IQGAP1 was down-regulated by H1 in the WM1158 
expression profile suggesting this gene family may be a common target of NM23.  
IQGAPs are a highly conserved class of proteins which alter cytoskeletal 
structure and associated signaling events, exerting influence on CDC42, Rac, E-
Cadherin, and -Catenin, among others (131-134).  Functionally these proteins 
have shown dependence on Rac1 binding for their activity which is important for 
cell-cell adhesion and motility through regulation of F-actin dynamics. (135)  
Modulation of signaling through Ras and PI3 kinase pathways has also been 
shown for IQGAPs, controlling aspects of chemotaxis possibly through 
differential regulation of these cascades (135).   
 These three genes, IQGAP2, LCN2, and BRAP, have all demonstrated 
importance for a variety of mitogenic signaling events.  The fact that they all feed 
in to many of the same branches of the MAP kinase cascade suggested potential 
importance of this pathway in mediating H1-dependent motility suppression.  The 
role of these genes in the WM793 melanoma model was addressed using 
lentivirus-based shRNA-mediated gene silencing.  RNA interference is a rapid 
and effective means of assessing relevant functions associated with any given 
gene.  Lentiviral delivery systems are commonly used based on their ability to 
infect both cycling and non-cycling cells, stable integration into the host cell 
genome and proving to be less prone to silencing during development allowing 
for use in embryonic stem cell studies (136).  Transduced cells exhibiting 
antibiotic resistance and loss of the targeted transcript were subjected to wound 
healing assays and relative motility was measured.  Of all the genes tested in 
these experiments, it appeared that the up-regulation of BRAP as well as the 
suppression of IQGAP2 contributed the most to the observed H1-dependent 
phenotypes.  The coordinated yet opposite regulation of these two genes would 
indicate H1 is controlling a set of genetic events which may be ultimately 
modulating propagation of specific yet unidentified signals, potentially underlying 
the impedance of metastatic progression.  
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Materials and Methods 
Cell lines and culture:  293T cells were a kind gift of Dr. M. Kilgore (University of 
Kentucky, Lexington, KY).  WM793 melanoma cell lines were maintained at 5% 
CO2, 37
o C in TU 2% growth medium composed of MCDB153: Leibovitz-15 (4:1; 
v:v) (Sigma, St. Louis, MO:Gibco, Carlsbad, CA) with 2 mM CaCl2 (Fisher 
Scientific, Pittsburgh, PA), 5 g/mL insulin (Sigma, St. Louis) and 2% fetal bovine 
serum (FBS) (Gibco).  293T cells were grown at 10% CO2, 37
o C in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% FBS, 1 mM non-
essential amino acids (Lonza, Allendale, NJ), 1 mM L-glutamine (Gibco), 100 
units/mL penicillin and 100 g/mL streptomycin (Lonza).   
 
Lentivirus Expression Vectors, Virus Production and Infection: Packaging 
plasmids pRev, pVSV-G, and pMDL.go.RRE (137, 138) were kind gifts of Dr. 
Louis Hersh (U. of Kentucky).  shRNA-encoding Lentiviral expression vectors 
(pLKO.1-puro) were purchased from the Sigma-Aldrich MISSION line (St. Louis, 
MO).  For generating recombinant lentivirus, 2 x 106 293T human embryonic 
kidney cells, an efficient lentivirus packaging cell type, were seeded in 100 mm 
dishes, and transfected using the calcium phosphate method 24 hours later.  
Transfection media was changed following overnight incubation and lentiviral 
containing media was harvested ~40 hours later, centrifuged at 1500 x g for 5 
minutes, then flash frozen in 0.5 mL aliquots and stored at -80o C.  Viral titer was 
determined using QuickTiter™ Lentivirus Titer Kit (Lentivirus-Associated HIV 
p24) (Cell Biolabs, San Diego, CA) and concentration of viral particles for each 
preparation were normalized to one another based on presence of p24 viral coat 
protein.  
 
Lentiviral Infection:  Cells were seeded 1 x 105 in 100mm dishes and infected 24 
hours later at 10 MOI then incubated overnight.  Viral containing media was then 
removed and fresh TU 2% was added for 72 hours.  Cells were then subjected to 
2 g/mL puromycin for a minimum of 14 days, changing media every 3-4 days.  
Selected clones were pooled and tested for target gene expression. 
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RNA isolation:  WM793 cells were initially seeded 1.5 x 105 in 100 mm culture 
dishes and grown for 3 days in TU 2% melanoma media to a confluence of 
~80%.  Total cellular RNA was harvested using RNEasy RNA Extraction Kit 
(Qiagen) according to the supplied protocol.  Concentrations were determined 
using a NanoDrop® ND-1000 (Invitrogen, Carlsbad, CA).   
 
PCR Analysis:  Total cellular RNA (1 g) was converted to cDNA using 
MultiScribe reverse transcriptase and random hexamer primers in 50 l reactions 
(Applied Biosystems, Foster City, CA).  50-200 ng of cDNA was used for PCR 
amplification in the presence of sequence specific, exon-spanning primers (Table 
4.1). PCR products were separated on 1.5% agarose gels and visualized with 
ethidium bromide.     
 
Wound Healing Assays:  “Scratch” assays were conducted in 6-well tissue 
culture plates.  3x105 WM793 cells were seeded per well and allowed to attach 
for ~16 hours under normal growth conditions.  TU 2% growth medium was then 
changed to protein-free culture medium and the cell’s were “starved” for 4 hours.  
A scratch was generated in the monolayer of cells with a 200 L pipette tip and 2 
washes with media were used to remove any loosely attached cells.  The cells 
were then grown for 48-72 hours in the absence of exogenous growth factors to 
reduce proliferation, at 37o C, 5% CO2.  For analyses, multiple images were 
captured (~4 per well) from the same area of the scratch in 24 hour intervals 
using light microscopy (4X) and a Nuance imaging system (CRi, Woburn, MA).  
Motile cells were counted and measured using ImageJ software (U.S. National 
Institute of Health, Bethesda, MD) (105). 
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Table 4.1 Primers Used For shRNA Validation 
Name  
 
Seq (5'-3')  
Tm 
(oC) 
GC 
content 
(%) 
Product 
length 
(bp) 
 
H1-(F) 
 
 
CATTGCGATCAAACCAGATG 
 
52.1 
 
 
45 
 
373 
H1-(R)  CAAGCCGATCTCCTTCTCTG 55  55  
LCN2(F)  AGGCCTGGCAGGGAATGCAA 62.4  60 424 
LCN2(R)  ACACTGGTCGATTGGGACAGGG 61.2  59  
BRAP(F)  GCGCAGTGCCATGCTGTGTA 61.1  60 460 
BRAP(R)  TGGCTCGGGCGTTTGACAGT 62.1  60  
IQGAP2(F) TTGCTGGGGTCGCTGGGAGA 63.8  65 312 
IQGAP2(R) TGCACGGCTCACCATGTCCG 62.9  65  
 
(F)-Forward primer 
(R)-Reverse primer 
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Results 
Gene Targets Are Effectively Knocked-down Using shRNA Lentivirus 
Constructs 
 Gene targets of interest were identified from exon array analysis of H1 
overexpression in melanoma cells and selected for further analysis based upon 
their differential expression tracking with H1-dependent motility suppression.  In 
order to examine the function of these genes in WM793 cells, lentiviral delivery of 
shRNA molecules was used.  Groups of 4 to 5 lentivirus-based shRNA 
constructs targeting each individual gene were tested, and those showing the 
greatest efficiency of knock-down were chosen for continued study.  Stable 
transductants were generated in both the WM793-pCI and –H1-WT cell lines with 
silenced expression of NM23-H1, LCN2, BRAP, IQGAP2, as well as empty-
vector controls.  An additional set of cells co-infected with BRAP and LCN2 
shRNA to counteract H1-dependent simultaneous induction to both genes were 
also created.  Examples of typical reductions to expression of NM23-H1 are 
assessed with PCR analysis or immunoblotting as indicated (Figure 4.1). 
 Once the effectiveness of lentiviral infection was confirmed, cell lines were 
monitored in culture for presence of toxicity or gross morphological changes.  
Interestingly, reducing expression of BRAP, either on its own or in combination 
with LCN2, increased the presence of extremely long, bipolar dendrites from the 
WM793 cells in both pCI and H1wt cells, in agreement with what would be 
predicted in this system.  Also, a shift in the morphology of the H1-transfectants 
that received the NM23-H1 shRNA was observed.  Silencing H1 caused cells to 
acquire a similar morphology to that of the more aggressive pCI control cells, 
confirming this effect is mediated by the H1 gene and was not due to a non-
specific off-target effect (Figure 4.2).   
 
Silencing genes fitting the motility profile recapitulates the observed 
phenotype 
 The gene profile tracking with H1-dependent motility suppression 
implicated BRAP as a potential mediator.  From here, additional gene targets  
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A. 
NM23-H1
shRNAuninfected
Empty 
vector
PHPHP H
H1
 
  
B. 
NM23-H1
NM23-H1
shRNA
Empty 
vector
 
Figure 4.1 Validation of H1 Silencing in WM793 Transfectants.  Effectiveness 
and persistence of H1 knockdown was confirmed following lentiviral infection and 
puromycin selection.  Stable integration and expression of the shRNA construct 
was confirmed using (A) RT-PCR and (B) immunoblotting analysis.  P = pCI; H = 
H1 
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+ H1-shRNA + H1-shRNA
WM793-pCI WM793-H1wt
Empty vectorEmpty vector
 
Figure 4.2 H1-expression Alters the Morphology of WM793 Cells.  As 
indicated by the two pictures at the top of the panel, control cells (top left) lacking 
H1 expression exhibit dendritic processes and much more elongated 
morphologies than those overexpressing H1wt (top right).  Targeted silencing of 
H1 in the stable transfectants (bottom right) causes the reversion to the 
morphologies found among pCI control cells. 
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were selected based on functional similarity to BRAP in hopes of uncovering 
networks of genes which may coordinate the effects of H1.  As a result, stable 
cell lines exhibiting silenced expression of H1, LCN2, IQGAP2, and BRAP 
(Figure 4.3) were generated and characterized.  Cell lines were cultured and 
compared based on relative motility in wound healing assays. (Figure 4.4)  
Manipulation of two of these genes in particular, IQGAP2 and BRAP, strongly 
suggests their functional involvement in facilitating the actions of H1.   
As mentioned, BRAP and LCN2 showed elevated transcript levels in 
response to H1 overexpression suggesting potential roles in promotion of H1-
dependent effects.  Indeed, BRAP down-regulation induced the migration of both 
pCI and H1-WT transfectants while also exacerbating the presence and length of 
filipodial processes extending from the motile cells.  Silencing LCN2 did not 
appear to induce the same response as the BRAP shRNA.  These LCN2-shRNA 
cells had the same degree of motility and similar morphologies as the control 
cells.  Additionally, the response of these melanoma cells when both BRAP and 
LCN2 were silenced simultaneously did not appear to be exacerbated beyond 
BRAP knock-down alone, further indicating that the LCN2 gene product is not a 
significant factor in this context. 
 On the other hand, there was one gene tested that was repressed by H1 
up-regulation and fit the motility profile, IQGAP2.  Blocking expression of this 
gene was expected to suppress migration as it was inversely correlated with 
NM23.  The results supported this prediction as IQGAP2 appeared to be an 
extremely important mediator of motility in this cell line, with profound reductions 
to numbers of migrating cells in the absence of this gene. In fact, inhibiting the 
IQGAP2 gene had a similar effect on the WM793 cells as H1wt overexpression 
suggesting that H1-dependent reductions to IQGAP2 levels within the cell may 
play a critical role in suppressing melanoma cell motility.  
 The results of the RNA interference studies have suggested additional 
novel roles for H1 in altering expression of molecules previously linked to 
modified signal transduction in mediating reductions in cancer cell motility.  
Evidence of functional contributions from BRAP on motility suppression has once  
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Figure 4.3 Silencing of IQGAP2, BRAP and LCN2.  WM793 transfectants were 
tested for stable integration of shRNA constructs following antibiotic selection.  
RT-PCR and agarose gel electrophoresis was used to confirm efficacy of the 
lentiviral infection directed to H1 gene targets (A) LCN2, (B) BRAP, and (C) 
IQGAP2.  
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Figure 4.4 BRAP and IQGAP2 Are Mediators of H1-Dependent Motility 
Suppression.  WM793 transfectants were infected with lentivirus containing 
shRNA expression vectors targeting the genes listed along the x-axis and 
subjected to wound healing analysis.  A scratch was generated along the cell 
monolayer and cultures were grown 48 hours in serum-free medium.  Phase-
contrast images were gathered at 4X magnification every 24 hours.  ImageJ 
software was used to determine scale and count individual motile cells.  *H1wt 
dependent effects that exhibit statistical significance vs. pCI as determined by 
nested 1-way ANOVA and Dunn’s test. 
 
 
 
 
 
 
 
 
 
 
 
WM793-pCI 
WM793-H1-WT 
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again implicated the KSR molecule as a functional target of H1 in some cancers.  
A simplified model is proposed, illustrating the multiple levels of H1-dependent 
regulation of a KSR containing branch of the MAPK signaling cascade, and small 
GTPases including Rac, Rho and Cdc42, incorporating what has been presented 
previously by others with the novel findings herein (Figure 4.5).          
 
Conclusions 
 The results of the current round of experiments indicate a novel role for 
NM23-H1 in altering the expression of key molecules previously shown to 
regulate intracellular signal transduction in other systems.  Modulation of genes 
BRAP and IQGAP2 facilitates, at least in part, H1-dependent motility suppression 
and may be found to be of further importance in prevention of melanoma 
metastasis.  The fact that LCN2 did not appear to increase cell motility in the 
absence of BRAP would suggest that LCN2 is either acting upstream of the point 
of deregulation, or is not mechanistically involved with this phenotype at all.  
Supposing hyperactive signaling through the B-Raf mutation V600E is a driving 
force in the biology of this particular cancer model, it makes sense that LCN2 
regulation would be innocuous to the cell as it is upstream of B-Raf, whereas 
BRAP directly inhibits Raf-MEK propagation.  Furthermore, with separate 
descriptions of physical interactions with H1 and BRAP independently for KSR, it 
is possible that H1 and BRAP are both found in a protein complex with KSR and 
perhaps even functionally interact with one another, although there is no known 
description of this phenomenon.     
The position of IQGAP2 in this model is not quite so clear, but again, its 
profound effect on the behavior of WM793 cells would suggest that, if via MAPK 
modulation, it may be acting at or below B-Raf signaling in the current schematic, 
or perhaps through a parallel route.  The high degree of cross-talk that exists 
among many of these oncogenic transduction pathways makes it difficult to 
accurately depict all of the relevant interactions occurring within a tumor cell.    
 It is becoming increasingly evident that the Raf-MEK pathway, as well as 
the small GTPases Rac, Cdc42 and Rho, contributes quite extensively to the  
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Figure 4.5 Proposed Model for H1-mediated Regulation of a Ras Signaling 
Pathway.  NM23-H1 regulates a number of components of the Ras cascade 
including TIAM1, IQGAP2, BRAP, KSR and LCN2.  The manner in which H1 
affects these molecules indicates negative regulation of signal propagation.  
Activation or induction is indicated with green or blue arrows while repression is 
illustrated with red blocked lines.  The three novel genes identified in this study 
as being transcriptionally regulated by H1 are designated by dashed lines.  
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progression of many melanomas.  A wealth of experimental data has proven that 
activation of not only Raf signaling, but also abnormal function of N-Ras, PTEN, 
and Akt, strongly correlate with melanomagenesis (139).  In fact, studies by Dr. 
M. Herlyn have shown dependence on MEK and Akt signaling pathways in 
melanoma cells of both VGP and metastatic origin and that inhibition of 
oncogenic activity with pharmacological compounds targeting MEK and PI3K 
were able to completely abolish tumors (140).  Clinical studies with treatments 
directed towards mutated B-Raf have also shown promise in advanced 
melanomas (141).  As this pathway seems to be so important for sustaining 
melanoma tumor growth, it is quite intriguing to see it potentially targeted on so 
many different levels by a single metastasis suppressor gene.  Perhaps 
reactivation of H1 gene expression could mimic the downstream effects of 
pharmacological B-Raf inhibitors and could be exploited as a novel therapeutic 
for the treatment of melanomas harboring the V600E mutation.  Moreover, 
considering the broad range of H1 targets in this pathway, it is quite possible 
elevating NM23 expression could be just as successful in preventing metastasis 
of Ras or Raf driven melanomas. 
 
 
 
 
 
 
 
 
 
 
 
Copyright ©Joseph Robert McCorkle 2010 
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CHAPTER FIVE 
 
Discussion 
  
Recent progress in clinical outcomes using targeted therapies for treating 
melanoma has produced renewed confidence in the ability to design highly 
effective pharmacological small molecules, making the advent of personalized 
medicine a much more likely and logical approach.  While quite a bit is unknown, 
extensive characterization of the development and progression of melanoma has 
revealed a great deal of information about the disease.  For example, findings 
from a number of studies have identified activating mutations to BRAF or NRAS 
driving tumorigenesis, providing the basis for a number of clinical trials targeting 
the associated oncogenic signaling of these gene products.  However, in spite of 
advancements made, melanoma incidence continues to rise.  While only 
accounting for about 4% of newly diagnosed skin cancers, it remains the most 
deadly, causing 79% of skin cancer deaths (142), with a 5-year survival rate 
under 5% (143).  The elevated mortality associated with melanoma is based on 
its ability to readily metastasize.  As with most aggressive cancers, metastatic 
melanoma displays inherently high degrees of plasticity, exhibiting multipotency, 
a trait commonly seen in human embryonic stem cells (ESC).  This observation 
has led to a great deal of interest on stem cell-like properties of many metastatic 
cancers.  The existence and consequences of distinct populations of cancer stem 
cells on metastatic progression is currently an area of intense investigation, 
however, common aspects of signaling pathways mediating multipotency of both 
tumor cells and ESCs has been described (144). 
While the genetic and epigenetic mechanisms governing this increased 
plasticity are incompletely understood, it is highly likely that the same mechanism 
used by metastatic melanoma cells to rapidly adapt to various 
microenvironmental cues probably underlies greater therapeutic resistance 
associated with melanoma.  Thus, continued investigation into the basic biology 
of melanoma, as well as normal melanocytes, is crucial for finally achieving 
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successful pharmacological intervention for lethal metastasis, as it appears so 
close to becoming a reality for melanoma.  As previously mentioned, the 
discovery of deregulated MAPK signaling in the majority of melanomas has 
produced an onslaught of clinical trials.  Initial studies using a broad spectrum 
Raf inhibitor sorafenib (Bayer) on its own were disappointing, however, the next 
generation of BRAF inhibitors, both specific or more general targeting of multiple 
kinases including BRAF, are currently being studied clinically.  Preliminary results 
of phase 2 trials for the selective inhibitors PLX4032 (Plexxikon) and 
GSK2118436 (Glaxo-Smith-Kline) as single use agents in patients with mutated 
BRAF have been positive, however, as with many prior melanoma treatments, a 
number of those who initially responded have since become resistant (145).  In 
light of these studies, it is clear that BRAF is an important therapeutic target for 
melanoma yet targeting it only represents part of the solution.  It is becoming 
apparent that the most aggressive melanoma cells are able to circumvent 
signaling pathways disrupted pharmacologically, possibly by using parallel, 
convergent routes however, combining agents which can disrupt multiple 
networks may prove much more promising for overcoming resistance. (146)  
Indeed, current reports have indicated that mutated BRAF cooperates with PTEN 
loss to produce metastatic melanoma, suggesting that targeting Raf-MEK 
signaling along with PI3K activity may be necessary for eradicating certain types 
of melanoma (147). 
The ramifications from these findings extend to the melanoma model used 
for the NM23 studies presented herein.  It had been previously reported that the 
WM793 and 1205LU cell lines both harbored the V600E activating mutation to the 
BRAF gene (148).  An additional acquired anomaly thought to contribute to the 
metastatic competency of the 1205LU cells is the loss of the tumor suppressor 
PTEN through inactivating mutation, suggesting a genetic basis for the 
differences in aggressiveness between the two lines (149).  This is extremely 
informative as studies using these cell lines in three-dimensional cell culture 
models showed metastatic 1205LU melanoma cells exhibited resistance to MEK 
inhibitors (U0126 and PD 98059) and a PI3K inhibitor (LY294002) when 
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administered individually (140).  Interestingly, the same experiments found VGP 
WM793 cells exhibited toxicity and cell death following 72 hours of U0126 
treatment at doses that had no effect on survival of 1205LU cells (1 and 10 M).  
Similar results were seen using the PI3K inhibitor alone, however, co-
administration of the two inhibitors was effective at synergistically blocking 
viability and invasiveness of the 1205LU metastatic melanoma cells (140).  
These results strongly indicate a cooperative function and dependence on 
multiple signaling pathways for promotion of melanoma metastasis while 
exposing the short-comings of similar single-agent therapeutics in treating 
malignant cancers.  
 The fact that aggressive melanoma cells are able to circumvent disruption 
of critical signaling events used to promote survival and expansion makes the 
class of metastasis suppressor genes that much more remarkable.  If these data 
accurately reflect the metastatic process in humans, suppressors must be able to 
negatively impact progression on multiple levels, as the most aggressive cells will 
possess the ability to adapt and respond to selective pressure much more rapidly 
than normal cells.  Highly plastic cancers, in theory, would overcome a single 
barrier implemented by a metastasis suppressor gene with relative ease.  
Therefore, it seems likely that the scope of functions of a MSG would have to 
reach well beyond an individual target if successful suppression is to be 
achieved.  On the other hand, the unique feature of metastasis suppressors is 
their inability to affect primary tumor growth suggesting profound differences 
between metastatic clones and most cells in the primary tumor.  The processes 
underlying the disparity in aggressiveness are the most likely targets of 
suppressor action and as a result, understanding this class of genes helps to 
identify various signaling events important to metastasis.  Further identification 
and characterization of relevant signaling pathways is required in order to 
elucidate genes and transcription factors activated at the endpoint of a cascade 
which may play specific, yet more global roles in metastasis, as some have 
suggested is the case for the transcription factor NF B (150-152). 
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 It is no surprise that the data here would indicate a role for H1 in 
modulating cell signaling as this feature is common among MSGs (113).  
Additional evidence further implicates H1 in multiple pathways with reports of 
physical interactions with Rad, Tiam1 and KSR.  The findings presented here 
that H1 can also modify expression of other affiliated genes, specifically BRAP 
and IQGAP2, solidifies the notion that NM23 may be exerting influence upon 
multiple levels of signaling.  Whether these particular interactions are responsible 
for H1-dependent metastasis suppression is unclear but is sure to be an area of 
continued investigation. 
 The microarray studies and subsequent pathway analyses illuminated 
broader mechanisms through which NM23 may be impacting tumor progression.  
The high proportion of ribosomal and RNA binding proteins found to be regulated 
by H1 (~ 9% of significant genes) implicates translational control as another 
possible means for suppressing metastasis.  This is in addition to previously 
described roles in RNA processing (106) and functional interactions with 40S 
ribosomal protein S3 (RPS3) (153).  Of particular interest to this study, RPS3 
was shown to cooperate with H1 to influence ERK signaling in HT1080 cells 
while appearing to have an additional role in NF B complexes (154).  Years of 
research have uncovered extensive interdependence between cell signaling and 
translational control.  Both Ras and PI3K mediated signal transduction induce 
translational machinery and activate the mTOR complex 1 as well as a variety of 
eukaryotic initiation factors (eIF), resulting in translation of genes involved in cell 
growth, proliferation and tumor progression (155-157).  While the extensive 
interactions between ribosomal proteins, initiation and elongation factors, and 
mRNA are reviewed in detail elsewhere (158), the favorable outcomes from 
clinical trials testing inhibitors of specific eIFs and mTOR underscore the 
contributions of translational aberrancies in tumor initiation and maintenance 
(159-162).  These studies also lend credence to the idea that H1 regulation of 
genes controlling translation, via expression changes, direct physical interaction 
or signal alterations, may play important roles in mediating the H1-dependent 
phenotype.          
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 Cancer research has been greatly influenced by the concept of cancer 
stem cells in recent years as characteristics of many aggressive malignant 
cancers resembled those of embryonic stem cells in having a high propensity for 
self-renewal and proliferation (163).  In the context of this theory, H1and other 
metastasis suppressors may be exerting effects on a stem cell-like subpopulation 
of cancer cells within a tumor which would be responsible for generation of 
metastatically competent progeny.  The highly dedifferentiated stem-like cells are 
thought to give rise to slightly more committed progenitor cells that are still 
capable of becoming more specialized cell types, indicating that even the 
progeny are highly undifferentiated.  As differentiation is considered to be an 
irreversible process, the cancer stem cells and their offspring have not yet 
transitioned to a designated cell fate and are equipped with substantial plasticity, 
much like an immature cell during development.  Therefore, these 
dedifferentiated cells should easily adapt and thrive in a number of tissue 
microenvironments, much like the behavior of embryonic and metastatic cells.   
 This concept may help explain some of the data presented here.  The 
motility associated morphology observed in scratch assays with WM793 cells is 
reminiscent of an immature melanocyte (164).  Melanocytes of both adults and 
newborns are typically spindle shaped however early melanocytes are typically 
unpigmented and bipolar whereas differentiated melanocytes produce melanin 
and are polydendritic (165).  The high degree of similarity between the 
morphology of immature melanocytes and the aggressive WM793 cells is 
intriguing in light of the cancer stem cell theory.  Motile cells displaying bipolar 
dendrites are perhaps arising from a stem cell compartment and are being 
observed at a similar point in the primordial lineage as the early melanocyte.  If 
indeed this is the case, these cells would be expected to possess the associated 
increased plasticity as well.  The absence of this sub-population of cells in the 
H1-transfectants indicates a suppressive effect on this minority, possibly 
representing metastatically competent clones which would be selectively targeted 
by a metastasis suppressor.  It is plausible that H1 is impeding these cells 
through the proposed model of intracellular signal modulation, as shRNA studies 
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would indicate that IQGAP2 and BRAP both play important roles in the observed 
phenotype.  Multiple actions of NM23 may be leading to more tightly regulated, 
highly specific transduction which perhaps drives these cells towards a more 
differentiated cell fate, quenching the multipotency and plasticity of these cells 
and in turn, suppressing their metastatic capability. 
 In order to ever realize any clinical benefit from metastasis suppressor 
genes like NM23, a feasible method for reintroduction of the gene must be 
discovered.  The most likely scenarios involve the identification of 
pharmacological compounds that can induce expression or the development of 
safe and effective gene therapy systems, as preliminary studies would suggest is 
possible (166-168).  However, it becomes a question of when administration of 
such a treatment would actually be effective.  If metastatic disease is already 
present, it is possible that a MSG would be innocuous, other than to possibly 
prevent further dissemination from the metastatic lesions themselves.  This is 
because some MSGs, in particular H1, may affect key aspects of tumor spread 
independently of tumor growth.  Therefore, an already established metastatic 
lesion may not regress upon forced expression of a MSG.  Early detection of a 
primary tumor and administration of treatment prior to successful secondary site 
colonization would be required for a positive response, luxuries rarely afforded in 
clinical settings.  It is possible that H1 could still impact dormant micrometastases 
at a site such as the pulmonary capillary beds that have yet to fully establish 
themselves, as these cells most likely must undergo further adaptation in order to 
colonize and would require a greater degree of plasticity than perhaps those of a 
full blown metastasis.  Nonetheless, screening of pharmacological libraries is 
sure to identify novel compounds that can initiate de novo transcription of MSGs 
and will provide some therapeutic benefit, at least for a specific subset of 
patients.   
An alternate approach was presented here with the identification of genes 
differentially expressed in an H1-dependent manner.  The gene profile was used 
as a discovery tool for novel accessory proteins which facilitate the activity of H1.  
Characterization of factors mediating H1-dependent metastasis suppression 
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could lead to the development of novel therapeutics independent of H1 
expression.  Indeed, the success of B-Raf inhibitors (e.g., PLX4032) in clinical 
trials is of no surprise in light of the microarray data as the activity of this 
serine/threonine protein kinase seems to be consistently targeted by H1, 
indicating proof of principle.  Further investigation into the complete mechanism 
used by H1 to modulate expression and signaling could stimulate new ideas for 
improving current treatment designs, preventing acquired resistance and 
enhancing the effectiveness against metastatic disease.           
 
Future Directions 
Before confidently accepting the role of H1 in modulation of MAPK signal 
transduction, a number of additional studies are in order.  First, thorough 
characterization of altered signaling dynamics mediated by H1 is desired.  
Identification of specific patterns of phosphorylation changes resulting from H1 
overexpression on effector molecules through the use of phosphor-proteome 
mass spectrometry analyses or simple phosphor-specific immunoblotting could 
greatly benefit our understanding of these processes.  Additional studies using 
pharmacological inhibitors of MEK, PI3K, B-Raf among others in the panel of 
NM23 transfectants would shed light on any synergistic effects H1 may have on 
oncogenic signaling.  
H1-dependent motility suppression is mediated at least in part by IQGAP2 
and BRAP expression levels in this model of melanoma, however, the role of 
these genes in metastasis is not yet known.  Animal models of tumor progression 
should be used to assess the contribution of these molecules to H1-mediated 
suppression of metastasis.  Stable cell lines harboring RNAi molecules could 
facilitate such studies by investigating the dependence on these gene targets for 
acquisition of H1-dependent phenotypes.  While it would be expected that these 
genes would indeed play important roles in metastasis due to the motility data, it 
is possible that the correlation between in vitro motility suppression and 
metastasis prevention in nude mice does not exist, as was realized with studies 
in 1205LU cells described in chapter 2. 
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A final area of investigation that should be pursued in light of this data is 
the possible negative influence of H1 on the cancer stem cell compartment.  
Analysis of effects levied against a stem-like cell by H1 could cause a paradigm 
shift concerning how we view a metastasis suppressor like H1.  Assuming the 
presence of such a niche exists in tumors, it is plausible for metastasis 
suppressors to act specifically on this tumor-initiating sub-population, perhaps by 
applying selective pressure and preventing the outgrowth of highly aggressive 
progeny cells or through elimination of the metastatically competent cancer stem 
cells themselves.  Isolation and purification of stem-like cells in order to assess 
basal levels of MSG expression would be an appropriate starting point, with the 
expectation that many genes in this class should exhibit low endogenous 
expression in this compartment.  If the prediction is true, the development of 
therapeutic strategies designed to induce H1 expression may hold a great deal of 
promise for clinical blockade of tumor progression and metastasis. 
 
 
 
 
 
 
 
 
 
 
Copyright ©Joseph Robert McCorkle 2010 
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Appendix 
 
MSG: metastasis suppressor gene 
NM23-H1 (H1): nucleoside diphosphate kinase A/ non-metastatic cells 1 
WT: wild-type 
Amino acid residue abbreviations: 
 A: alanine 
D: aspartic acid 
E: glutamic acid 
 F: phenylalanine 
 G: glycine 
 H: histidine 
 K: lysine 
 N: asparagine 
P: proline 
 Q: glutamine 
 S: serine 
 V: valine 
 Y: tyrosine 
DNA/RNA: deoxyribonucleic acid/ ribonucleic acid 
VGP: vertical growth phase 
RGP: radial growth phase 
CD: circular dichroism 
HPLC: high-pressure liquid chromatography 
90 
 
RT-PCR: reverse-transcriptase polymerase chain reaction 
SDS: sodium dodecyl sulfate 
UV: ultra-violet 
ATP: adenosine triphosphate 
NTP/NDP: nucleoside triphosphate/ nucleoside diphosphate 
EMT: epithelial to mesenchymal transition 
ESC: embryonic stem cell 
MAPK: mitogen activated protein kinase 
MEK: mitogen activated protein kinase kinase 
ERK: extracellular signal-regulated protein kinase 
B-Raf: v-raf murine sarcoma viral oncogene homolog B1 
Ras: Ras oncogene homolog 
PTEN: phosphatase and tensin homolog 
CDC42: cell division cycle 42 
Rac: ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) 
Rho: ras homolog gene family 
KSR: kinase suppressor of Ras 
Tiam1: T-cell lymphoma invasion and metastasis 1 
Rad: Ras-related associated with diabetes 
NFkB: nuclear factor kappa B 
PI3K: phosphoinositide-3 kinase 
BRAP: BRCA1 associated protein 
IQGAP2: IQ motif containing GTPase activating protein 2 
LCN2: lipocalin 2  
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